,ISRCTN,Title,Protocol/serial number,Ethics approval,Country of recruitment,Study stopped,Publication plan,Participant-level data,Basic results,Peer-reviewed publications,Funder,Sponsor,GRID id,FundRef id,Intention to publish date,Overall trial start,Overall trial end,Recruitment start,Recruitment end,Record last updated,Registered with ISRCTN,Overall trial status,Recruitment status,Prospective/retrospective,EudraCT number,ClinicalTrials.gov number,Primary study design,Condition,Condition category,Reason abandoned,Funding body type,Sponsor body type,Secondary study design,Trial setting,Trial type,Intervention type,Drug,Phase,Participant type,Age group,Gender,Target number of participants,Total final enrolment
53,ISRCTN16993428,GenOMICC study - Looking at DNA of patients with severe illness and injury to find the genes that cause some people to become very unwell and be admitted to intensive care,"IRAS 189676 (Scotland), IRAS 269326 (England/Wales)","1. Approved 08/12/2016, Scotland A REC (2nd Floor Waverley Gate, 2 - 4 Waterloo Place, Edinburgh, EH1 3EG, UK; +44(0)131 465 5678; Manx.Neill@nhslothian.scot.nhs.uk), ref 15/SS/0180/AM01/1 2. Approved 10/10/2019, Health Research Authority (Skipton House, 80 London Road, London, SE1 6LH, UK; +44 (0)20 7972 2545; hra.approval@nhs.net), ref: 19/WM/0247",Canada; Ireland; United Kingdom,,"Peer-reviewed scientific journals, internal report, conference presentation, publication on website IPD sharing statement The datasets generated during and/or analysed during the current study will be stored in a publicly available repository (genomicc.org/data). Type of data that will be shared: summary statistics for GWAS data When the data will become available and for how long: data will be available as soon as the analysis is completed to a satisfactory standard and will be maintained indefinitely. By what access criteria the data will be shared including with whom, for what types of analyses, and by what mechanism: Summary data will be publicly available to the public when the analysis has been completed to a satisfactory standard. Prior to the completion of the analysis, the summary statistics, or intermediate files may be made available to collaborators to assist with other analysis plans Whether consent from participants was obtained: consent has been obtained. The data to be shared openly is summary data and does not contain any identifiable information or data relating to individual genomes Comments on data anonymisation, any ethical or legal restrictions, any other comments: The summary data/summary statistics do not contain data relating to individual genomes or identifiable information. The exported data are summary statistics that do not contain individual information about individuals. The researchers are using variants with a minor allele frequency (MAF) of 1% which avoids identification of individuals using genetic data (because at least 1% of the population will have the minor allele of the variant which is enough people to be impossible to identify).",Stored in repository,,2020 genome-wide association study results in https://doi.org/10.1038/s41586-020-03065-y (added 01/06/2021) 2021 preprint results in https://doi.org/10.1101/2021.03.10.21252820 (added 01/06/2021) 2021 preprint results https://doi.org/10.1101/2021.03.04.21252931 (added 01/06/2021) 2021 preprint results in https://www.biorxiv.org/content/10.1101/2021.04.21.440697v1 (added 01/06/2021),Sepsis Research (FEAT); Intensive Care Society; Wellcome Trust; Medical Research Council,Accord (United Kingdom),grid.476075.7,http://dx.doi.org/10.13039/100010269; http://dx.doi.org/10.13039/501100000265,31/08/2030,01/12/2014,31/08/2029,04/07/2019,31/08/2029,25/06/2021,25/06/2021,Ongoing,Recruiting,Retrospectively registered,Nil known,Nil known,Multicentre prospective and retrospective interventional non-randomized study,Genetics of susceptibility and mortality in life-threatening infection Infections and Infestations,Infections and Infestations,,private sector organisationgovernment organisation,Research organisation,Non randomised studyNon randomised study,Hospitals,Screening,Genetic,,,Patient,Mixed,Both,40000,
58,ISRCTN16269648,Assessing the effectiveness of mouthwashes against SARS-CoV-2 before dental procedures,"IRAS 300106, CPMS 49628","Approved 14/06/2021, North of Scotland Research Ethics Committee (Summerfield House, 2 Eday Road, Aberdeen, AB15 6RE, UK; +44 (0)1224 558458; gram.nosres@nhs.scot), REC ref: 21/NS/0073",United Kingdom,,Planned publication in a high-impact peer-reviewed journal. The statistical analysis plan can be made available by contacting the main study contact should this be required. IPD sharing statement The data-sharing plans for the current study are unknown and will be made available at a later date.,To be made available at a later date,,,Johnson and Johnson,York Teaching Hospital NHS Foundation Trust,grid.439905.2,http://dx.doi.org/10.13039/100004331,28/06/2023,01/07/2020,28/06/2022,28/06/2021,28/06/2022,24/06/2021,24/06/2021,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,Single-centre interventional randomized controlled trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,government organisation,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Other,,,Patient,Mixed,Both,92,
89,ISRCTN23403781,Evaluating a school-based programme to prevent offending behaviour among young people,Nil known,"Approved 23/10/2020, by the Sheffield Hallam University ethical review committee (Sheffield Hallam University, Sheffield, S1 1AY, UK; Tel: not available; ethicssupport@shu.ac.uk), ref: ER27796305",United Kingdom,,"Protocol to be published as soon as trial registration is complete. Report to be published on the funder website. IPD sharing statement Personal data will be kept securely in a password protected folder accessible only to members of the evaluation team. The SHU evaluation team will comply with General Data Protection Regulation (GDPR legal basis: public task Article 6 (1e)) and the SHU Data Protection Policy Statement. Please refer to the link for more information: https://www.shu.ac.uk/about-this-website/privacy-policy/privacy-notices/privacy-notice-for-research After the evaluation is finished (in 2022), the pupil data collected (name, unique pupil number, date of birth) will be sent to the Department for Education (at which point Sheffield Hallam University cease to be responsible for the data), where it will be stored in a pseudonymised form to allow future research into the relationship between participating in DARE 25, educational attainment and criminal records. All personal data will be deleted at this stage. No pupils will be individually identifiable in the data archived. For more detail please see: https://youthendowmentfund.org.uk/wp-content/uploads/2020/10/YEF_Data_Guidance_Participants_Nov2020.pdf",Stored in repository,,,Youth Endowment Fund,Youth Endowment Fund,Missing GRID,,01/12/2021,01/10/2019,28/07/2021,01/11/2020,30/03/2021,08/07/2021,16/06/2021,Ongoing,No longer recruiting,Retrospectively registered,Nil known,Nil known,Cluster randomized trial,"Offending behaviours including hate, knife, drug and alcohol-related crime Not Applicable",Not Applicable,,,Charity,Cluster randomised trialCluster randomised trial,Schools,Prevention,Behavioural,,,Other,Child,Both,4000,3881.0
95,ISRCTN15162325,Social media campaign to increase COVID-19 testing in migrant groups,Nil known,"Not required. The study does not qualify as health research, but as a quality improvement study, since health outcomes are not measured and the intervention is similar to interventions that are being routinely implemented by the government.",Norway,,"Planned publication in peer-reviewed journal. IPD sharing statement: The datasets generated during and/or analysed during the current study are not expected to be made available due to legal (ethical and data privacy) reasons. However, we will attempt to prepare a synthetic version of the dataset if we receive requests from researchers who wish to replicate our analyses. The data code for our analyses will be made readily available for anyone who requests them.",Not expected to be available,,,Norwegian Institute of Public Health; Helsedirektoratet,Norwegian Institute of Public Health,grid.418193.6,http://dx.doi.org/10.13039/501100014232,01/11/2021,01/06/2021,22/06/2021,01/06/2021,14/06/2021,15/06/2021,15/06/2021,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Interventional cluster randomized trial,Testing for COVID-19 Infections and Infestations,Infections and Infestations,,government organisation,Government,Cluster randomised trialCluster randomised trial,Internet,Screening,Behavioural,,,Healthy volunteer,Adult,Both,234112,
96,ISRCTN38734433,"Better Outcomes for Everybody: a study to evaluate whether a new service delivered by community pharmacists in collaboration with physicians to asthma and COPD patients, improves disease control and is value for money, compared with usual care, during and after COVID-19",11130092020,"1. Approved 22/02/2021, Azienda Ospedaliero-Universitaria Policlinico ""G. Rodolico - San Marco"" Catania (via Santa Sofia 78 - 95123 Catania, Italy; +39 (0)95 3781855; comitatoeticoct1segr@policlinico.unict.it), ref. 47/2021/PO 2. Approved 29/03/2021, University of Central Lancashire (Preston Fylde Road, PR1 2HE, UK; +44 (0)1772 895583; ethicsinfo@uclan.ac.uk), ref: HEALTH 0163",Italy,,"The researchers are going to publish the study protocol, which includes the statistical analysis plan, in an open-access journal. The protocol was drafted according to the SPIRIT guidelines. The dissemination of the study will start immediately after publishing the protocol. Then, it will continue throughout the study using social media posts, patient events, third sector and public engagement events. Results of the trial will be presented at national and international conferences. They will be submitted as scientific manuscripts to peer-reviewed journals, and afterwards, published in non-peer-review publications in Italian and maybe other languages. The trial results aim to inform the policymakers, the Italian Ministry of Health, the Italian National Health Services, and all the other stakeholders that might benefit from the results. Results will be disseminated to service users and their families via media, healthcare professionals via professional training and meetings, and researchers via conferences and publications. IPD sharing statement All anonymised data will be stored in the repository UCLanData and clok. Process for requesting the data: http://clok.uclan.ac.uk/34599/1/Policies.pdf. Access to the data will be available only after the publication of all the trial results.",Stored in repository,,,SOFAD srl,SOFAD srl,Missing GRID,,01/10/2023,02/04/2020,30/06/2023,07/01/2022,07/03/2022,15/06/2021,15/06/2021,Ongoing,Not yet recruiting,Prospectively registered,Nil known,Nil known,Single-centre pragmatic parallel randomized controlled trial,"Asthma and Chronic Obstructive Pulmonary Disease (COPD) Respiratory Asthma, Chronic obstructive pulmonary disease, unspecified",Respiratory,,,Industry,Randomised controlled trialRandomised controlled trial,Community,Treatment,Behavioural,,,Mixed,Adult,Both,1000,
98,ISRCTN29153109,Acceptability of teledentistry during the COVID-19 pandemic in Saudi Arabia,HAPO-02-K-01 2-2021-O1-521,"Approved in 10/01/2021, Umm Al-Qura University Institutional Review Board (Umm Al-Qura University, Makkah, 24352, Saudi Arabia; +966 (0)125270000; irb.uqudent@uqu.edu.sa), ref: HAPO-02-K-012-2021-01-521",Saudi Arabia,,"1. Planned publication in a high-impact peer-reviewed journal 2. The protocol has been uploaded as an additional file (not peer-reviewed) IPD sharing statement: The datasets generated during and/or analysed during the current study are available from the corresponding author Dr Khalid Aboalshamat (ktaboalshamat@uqu.edu.sa) on reasonable request as an SPSS file (unidentified). The data will be available upon request for 2 years. Data can be accessed by the journal to which the researchers will submit their article, any Saudi Governmental authority, and researchers after careful consideration of their scientific intention to use. All data are anonymous with no identification.",Available on request,,,Investigator initiated and funded,Umm al-Qura University,grid.412832.e,,01/08/2021,10/06/2020,27/07/2021,17/02/2021,08/04/2021,08/07/2021,14/06/2021,Ongoing,No longer recruiting,Retrospectively registered,Nil known,Nil known,Parallel-group single-blind randomized controlled trial,Teledentistry Oral Health,Oral Health,,,University/education,Randomised controlled trialRandomised controlled trial,Other,Diagnostic,Other,,,Patient,Adult,Both,102,70.0
101,ISRCTN48554326,BioBlock nasal spray against COVID-19,Protocol v1,"Approved 26/04/2021, Research Ethics Committee of the University of Tartu (University of Tartu, Raekoja plats 9, 51004 Tartu, Estonia; +372 737 6215; eetikakomitee@ut.ee), ref: 339/T-1",Estonia,,Planned publications in a high-impact peer-reviewed journal. IPD sharing statement: The data sharing plans for the current study are unknown and will be made available at a later date.,To be made available at a later date,,,CHEMI-PHARM AS,University of Tartu,grid.10939.32,,30/12/2021,10/02/2021,30/08/2021,12/05/2021,07/08/2021,14/06/2021,14/06/2021,Ongoing,Recruiting,Retrospectively registered,Nil known,Nil known,Cluster randomized triple-blinded controlled trial,Prevention of COVID-19 (SARS-CoV-2 infection) among in household contacts of SARS-CoV-2 positive individuals Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,,University/education,Randomised parallel trialRandomised parallel trial,GP practices,Prevention,Device,A nasal spray containing colostrum preparation of SARS-CoV-2 antiviral antibodies,Phase II,Mixed,Mixed,Both,372,
117,ISRCTN31161020,Reducing stress in the workplace using a digital intervention designed to improve employee wellbeing and help them stay engaged and productive in work,BSREC 45/20-21,"Approved 25/01/2021, Biomedical Sciences Research Ethics Committee (University of Warwick, Coventry, CV4 7AL, UK; +44 (0)24 765 73123; BSREC@warwick.ac.uk), ref: BSREC 45/20-21",United Kingdom,,Planned publication in high-impact peer-reviewed journals. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date.,To be made available at a later date,,,Midlands Engine,University of Warwick,grid.7372.1,,01/04/2023,25/01/2021,01/04/2022,11/06/2021,17/09/2021,08/06/2021,08/06/2021,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,Multicentre interventional waitlist randomized-controlled trial,Prevention and treatment of anxiety and depression in employees from across the Midlands region in the United Kingdom. Mental and Behavioural Disorders,Mental and Behavioural Disorders,,,University/education,Randomised waitlist controlled trialRandomised waitlist controlled trial,Internet,Treatment,Behavioural,,,Patient,Adult,Both,420,
128,ISRCTN82492510,Kidney-specific psychosocial assessment and support,"1, IRAS 296551",Not provided at time of registration,United Kingdom,,Planned publication in a peer-reviewed journal and conference presentation. IPD sharing statement The dataset will not be made available due to the small numbers and single centre and high risk of re-identification. The data will be held on secure institutional servers.,Not expected to be available,,,British Renal Society; Kidney Care UK,Royal Devon and Exeter Hospital,grid.416118.b,http://dx.doi.org/10.13039/501100000389,01/09/2023,16/02/2021,01/09/2022,02/08/2021,01/08/2022,12/05/2021,07/06/2021,Ongoing,Not yet recruiting,Prospectively registered,Nil known,Nil known,Single-centre prospective single-blind wait-list individually randomized controlled feasibility trial,Common mental health difficulties for people with kidney disease Mental and Behavioural Disorders,Mental and Behavioural Disorders,,private sector organisation,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Behavioural,,,Patient,Adult,Both,36,
136,ISRCTN15317247,Using text messages to boost COVID-19 vaccine booking rate,IRAS 298649,"Approved 20/4/2021, South West - Cornwall & Plymouth Research Ethics Committee (Level 3, Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT, UK; +44 (0)207 104 8019; cornwallandplymouth.rec@hra.nhs.uk), ref: 21/SW/0055",United Kingdom,,"We intend to disseminate the findings from this study in the following forms: Peer reviewed scientific journals (TBD) Conference presentations (TBD) Internal reports Publication on organisational websites Blog posts Other publications and media Final decision on publication rests with the study sponsor. IPD sharing statement: The datasets generated during and/or analysed during the current study are not expected to be made available. NHSEI remains the data controller of the data. No plans for releasing the data have been discussed with NHSEI, and given the sensitive nature of the topic (COVID-19 vaccination rates), we expect NHSEI not to wish to make the data available.",Not expected to be available,,,NHS England and NHS Improvement,National Health Service,grid.451052.7,,01/07/2022,15/03/2021,01/07/2021,07/06/2021,13/06/2021,08/07/2021,03/06/2021,Completed,No longer recruiting,Prospectively registered,Nil known,Nil known,Interventional randomized controlled trial,Increasing uptake of COVID-19 vaccination among eligible adults aged 18 - 29 years in England Not Applicable,Not Applicable,,,Government,Randomised controlled trialRandomised controlled trial,Home,Other,Behavioural,,,Healthy volunteer,Adult,Both,4270000,
142,ISRCTN23016116,Effect of prone positioning in patients with severe SARS-CoV-2 pneumonia treated with noninvasive ventilation,"Protocol version 1.0 March 31st, 2021 Ethics committee protocol number: 0046392","Approved 05/01/2021, Comitato Etico Interaziendale A.O.U. Città della Salute e della Scienza di Torino, (Interhospital Ethics Committee-AOU City of Health and Science of Turin, Corso Bramante 88/90, 10126, Turin, Italy; +39 11-6331633; no email provided), ref: 0046392",Italy,,"We planned to publish the results of this controlled trial to an international journal following peer review. IPD sharing statement: The datasets generated during and/or analysed during the current study referring to de-identified individual patients will be available upon request from the PI Dr Giovanni Musso (phone: +39-11-19101244; e-mail: giovanni_musso@yahoo.it) since study publication for up to 5 years. Patients are required to consent to make their deidentified data publicly available for up to 5 years upon giving consent to study participation, as clearly stated in the protocol approved by local Ethics committee.",Available on request,,,Ospedale HUMANITAS Gradenigo,Ospedale Humanitas Gradenigo,grid.417225.7,,31/08/2021,15/12/2020,30/07/2021,05/01/2021,30/06/2021,02/06/2021,02/06/2021,Ongoing,No longer recruiting,Retrospectively registered,Nil known,Nil known,International non randomized controlled trial,Moderate-to-severe acute hypoxemic respiratory failure due to COVID-19 pneumonia Respiratory,Respiratory,,,Hospital/treatment centre,Non randomised studyNon randomised study,Hospitals,Treatment,Behavioural,,,Patient,Adult,Both,165,
175,ISRCTN17395671,Does an infant feeding helper service increase infant feeding practices in firstborn babies?,CPMS 46651,"Approved 18/05/2021, East of Scotland Research Ethics Service REC 1 (Tayside Medical Science Centre, Residency Block Level 3, George Pirie Way, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK; +44 (0)1382 383878; tay.eosres@nhs.scot), REC ref: 21/ES/0045",United Kingdom,,"The researchers plan to publish the protocol in the future. The chief investigator will coordinate dissemination of results. Results of this trial will be submitted for publication in a peer-reviewed journal. The manuscript will be prepared by CI or delegate and authorship will be determined by mutual agreement. A publication policy will be developed and approved by the CIG and TSC. Any secondary publications and presentations prepared by Investigators must be reviewed by the CIG. Manuscripts must be submitted to the NIHR in a timely fashion and in advance of being submitted for publication, to allow time for review and resolution of any outstanding issues. The authors must acknowledge that the trial was performed with the support of the NIHR and the University of Birmingham. Intellectual property rights will be addressed in the project agreement between the University of Birmingham and collaborating universities. A plain English summary will be sent to participants and available via the study website. IPD sharing statement The datasets generated during the current study will be available upon reasonable request from Professor Kate Jolly (c.b.jolly@bham.ac.uk) after the study is completed and the findings published. The anonymised quantitative data and transcribed qualitative transcripts from participants who have given consent to their anonymised data being stored for use in future ethically approved research will be available. Data requests will be considered by the research team and Birmingham Clinical Trials Unit, who will hold the data.",Available on request,,,"NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR129182",University of Birmingham,Missing GRID,,30/11/2024,01/10/2020,30/11/2023,01/07/2021,31/05/2023,24/05/2021,24/05/2021,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,"Randomized; Interventional; Design type: Process of Care, Other",Breastfeeding initiation and continuation Pregnancy and Childbirth,Pregnancy and Childbirth,,,University/education,Randomised controlled trialRandomised controlled trial,Home,Quality of life,Behavioural,,,Patient,Adult,Female,2730,
196,ISRCTN18003630,The development of an online advance care planning resource for nursing homes during a COVID-19 outbreak,IRAS 286725,"Approved 08/12/2020, Health and Social Care Research Ethics Committee B (HSC REC B, ORECNI office, Lissue Industrial Estate West, Rathdown Walk, Moira Road, Lisburn, BT28 2RF; +44 (0)28 95361400; RECB@hscni.net), ref: 20/NI/0173",United Kingdom,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date,To be made available at a later date,,,The Economic and Social Research Council as part of the UK Research and Innovation's rapid response to COVID-19; The Health and Social Care Research & Development Division (HSC R&D Division) of the Public Health Agency in Northern Ireland; Economic and Social Research Council; Public Health Agency,Queen's University Belfast,grid.4777.3,http://dx.doi.org/10.13039/501100000269; http://dx.doi.org/10.13039/501100001626,31/08/2022,08/06/2020,31/08/2021,18/02/2021,14/06/2021,18/05/2021,19/05/2021,Ongoing,No longer recruiting,Retrospectively registered,Nil known,Nil known,Multicenter prospective case study design,Care at the end of life during a COVID-19 outbreak Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,government organisationprivate sector organisation,University/education,Non randomised studyNon randomised study,Internet,Quality of life,Behavioural,,,Mixed,Adult,Both,99,
200,ISRCTN47802196,Effect of BCG vaccination for tuberculosis on COVID-19 in Brazil,401624/2020-0 (CNPq protocol number),"Approved 03/06/2020, Ethics Committee of the Institute of Collective Health (Federal University of Bahia, Basílio da Gama St., n/n – Canela, Salvador-BA, 40.110-040, Brazil; no telephone number provided; cepisc@ufba.br), ref: CAAE: 32820920.7.1001.5030",Brazil,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The datasets generated during and/or analysed during the current study are not expected to be made available due to property rights of the funding agency and ethics reasons related to confidentiality.,Stored in repository,,,National Council for Scientific and Technological Development (CNPq),National Council for Scientific and Technological Development,grid.450640.3,,01/12/2022,10/07/2020,31/12/2021,01/06/1996,01/06/1998,19/05/2021,19/05/2021,Ongoing,No longer recruiting,Retrospectively registered,Nil known,Nil known,Interventional cluster randomized trial,COVID-19 (SARS-CoV-2 infection) in persons who were previously given the BCG vaccine Infections and Infestations,Infections and Infestations,,,Government,Cluster randomised trialCluster randomised trial,Schools,Prevention,Biological/Vaccine,Bacillus Calmette–Guérin (BCG) vaccine,Not Applicable,Healthy volunteer,Adult,Both,200805,200805.0
219,ISRCTN73765130,Evaluating COVID-19 Vaccination Boosters,"CPMS 49379, IRAS 299180","Pending, South Central-Berkshire Research Ethics Committee (Easthampstead Baptist Church, South Hill Road, Bracknell, RG12 7NS; +44 (0)207 104 8224, +44 (0)207 104 8270; berkshire.rec@hra.nhs.uk)",United Kingdom,,Planned publication in a high-impact peer-reviewed journal IPD sharing statement: The data sharing plans for the current study are unknown and will be made available at a later date,To be made available at a later date,,,National Institute for Health Research,University Hospital Southampton NHS Foundation Trust,grid.430506.4,http://dx.doi.org/10.13039/501100000272,01/08/2023,01/02/2021,01/08/2022,01/06/2021,30/06/2021,25/06/2021,13/05/2021,Ongoing,No longer recruiting,Prospectively registered,2021-002175-19,Nil known,Three-stage multicentre single-blinded randomized adaptive phase II non-inferiority study,COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,government organisation,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Biological/Vaccine,"ChAdOx1-nCov19 (Oxford/AstraZeneca), BNT162b2 (Pfizer), NVX-CoV2373 (Novavax), NVX-CoV2373 (Novavax) Half Dose mRNA-1273 (Moderna), VLA2001 (Valnveva), VLA2001 (Valnveva) Half Dose, CVnCoV (Curevac), CVnCoV (Curevac) Half Dose, Men ACWY (Control arm)",Phase II,Healthy volunteer,Adult,Both,2886,
224,ISRCTN13857593,Study on the performance and safety of Sentinox in COVID-19 patients,STX-2021,"Approved 19/04/2021, Comitato Etico Regionale (Ospedale Policlinico San Martino – IRCCS, Largo Rosanna Benzi, 10 – 16132 Genova, Italy; +39 (0)10 010 555 4212; comitato.etico@hsanmartino.it)",Italy,,Data of the clinical study could be published in a journal as soon as the final study report is finalized. Data could be disseminated as abstract/poster or oral presentation in international scientific congresses. IPD sharing statement: The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication,Other,,,APR Applied Pharma Research SA,Applied Pharma Research (Switzerland),grid.487169.5,,01/12/2021,10/03/2021,31/07/2021,17/05/2021,30/06/2021,12/05/2021,12/05/2021,Ongoing,No longer recruiting,Prospectively registered,Nil known,Nil known,Single-centre open-label randomized controlled interventional study,COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,,Industry,Randomised controlled trialRandomised controlled trial,Other,Treatment,Device,,,Patient,Adult,Both,57,
242,ISRCTN13848929,"Does a new leaflet with information about the breast cancer screening program, its benefits and risks, affect participation in the screening program?",2019/8898/I,"Approved 09/10/2019, Clinical Research Ethics Committee of the PSMAR (CEIm – Parc de Salut MAR; Dr Aiguader, 88; 08003, Barcelona, Spain; +34 93 316 06 77; ceic-psmar@imim.es), ref: 2019/8898/I",Spain,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The datasets generated during and/or analysed during the current study are/will be available upon request from Margarita Posso (mposso@parcdesalutmar.cat) upon reasonable request.,Available on request,,2021 results in https://pubmed.ncbi.nlm.nih.gov/34217258/ (added 05/07/2021),Instituto de Salud Carlos III; Research Network on Health Services in Chronic Diseases,Parc de Salut,grid.418476.8,http://dx.doi.org/10.13039/501100004587,01/09/2021,01/09/2019,08/03/2020,30/09/2019,17/01/2020,05/07/2021,06/05/2021,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Single-center interventional cluster randomized controlled trial,Breast cancer screening program Cancer,Cancer,,government organisation,Hospital/treatment centre,Cluster randomised trialCluster randomised trial,Hospitals,Screening,Behavioural,,,Healthy volunteer,Adult,Female,9640,11119.0
249,ISRCTN18100261,Daily contact testing schools and colleges trial,R&D 434,"Approved 11/03/2021, Public Health England Research Ethics and Governance Group (PHE Research Support and Governance Office, Wellington House, 133-155 Waterloo Road, London, SE1 8UG, UK; +44 (0)1980 612922; elizabeth.coates@phe.gov.uk), ref: R&D 434",United Kingdom,,Planned publication in an open access peer reviewed journal IPD sharing statement: The datasets generated during and/or analysed during the current study are not expected to be made available due to lack of consent to share.,Not expected to be available,,,Department of Health and Social Care,Department of Health and Social Care,grid.57981.32,http://dx.doi.org/10.13039/501100000276,01/07/2022,01/01/2021,30/06/2021,22/03/2021,30/04/2021,04/05/2021,04/05/2021,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Pragmatic cluster randomized controlled study,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,government organisation,Government,Cluster randomised trialCluster randomised trial,Schools,Prevention,Behavioural,,,Mixed,Mixed,Both,200000,
257,ISRCTN12721265,Efficacy of mouth-rinses in reducing SARS CoV-2 viral load in the saliva of COVID-19 positive patients in Indonesia,2021,"Approved 25/03/2021, Institutional Review Board of Faculty of Dentistry, Trisakti University (Jl. Kyai Tapa No.1, RT.5 / RW.9, Tomang, Grogol Petamburan, West Jakarta City, Special Capital Region of Jakarta 11440, Jakarta, Indonesia; +628161908945; komisietikfkg@trisakti.ac.id), ref: 001/Dosen/KEPK/FKG/03/2021",Indonesia,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The datasets generated during and/or analysed during the current study are not expected to be made available due to confidentiality.,Not expected to be available,,,Universitas Trisakti,Trisakti University,grid.443412.4,http://dx.doi.org/10.13039/501100015726,31/05/2022,25/03/2021,20/10/2021,10/05/2021,10/06/2021,04/05/2021,30/04/2021,Ongoing,No longer recruiting,Prospectively registered,Nil known,Nil known,Single-center single blind interventional randomized clinical trial,Reducing the transmission of SARS CoV-2 virus in saliva of COVID-19 patients in Indonesia. Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,private sector organisation,University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Supplement,,,Patient,Adult,Both,68,
258,ISRCTN10839729,Anti-viral photodynamic therapy in COVID-19 management: a novel approach in treating patients in early infection stages,Covid2021001,No ethical approval required because of the emergency COVID-19 situation in Tehran/Iran in November 2020,Iran,,Planned publication in a high-impact peer-reviewed journal IPD sharing statement The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.,Other,,,Weber Medical,International Society for Medical Laser Applications,TESTING,,01/05/2021,02/09/2020,28/02/2021,01/11/2020,15/02/2021,29/04/2021,29/04/2021,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Interventional non-randomized study,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,Research organisation,Non randomised studyNon randomised study,Hospitals,Treatment,Mixed,,,Patient,Mixed,Both,140,140.0
269,ISRCTN79815558,COV-COMPARE: A study to compare the VLA2001 and AZD1222 vaccines against COVID-19 in adults,"VLA2001-301, IRAS 294164","Approved 20/04/2021, North West - Greater Manchester South Research Ethics Committee (3rd Floor, Barlow House, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)207 104 8221, +44 (0)207 104 8063; gmsouth.rec@hra.nhs.uk), REC ref: 21/NW/0125",United Kingdom,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement The current data-sharing plans for this study are unknown and will be available at a later date,To be made available at a later date,,,Department of Health and Social Care,Valneva (Austria),grid.420366.5,http://dx.doi.org/10.13039/501100000276,30/06/2023,20/07/2020,30/06/2022,28/04/2021,03/06/2021,07/06/2021,27/04/2021,Ongoing,No longer recruiting,Prospectively registered,2021-000522-97,Nil known,Randomized observer-blind controlled superiority Phase III study,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,government organisation,Industry,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Biological/Vaccine,"VLA2001, AZD1222",Phase III,Healthy volunteer,Adult,Both,4000,
288,ISRCTN12272130,"The comprehensive anaemia programme and personalized therapies (CAPPT) trial testing the effect of home visits, tailored iron therapy and women’s groups to reduce anaemia in pregnant women in southern Nepal",MR/R020485/1,"1. Approved 03/07/2019, Nepal Health Research Council's Ethics Committee (Ramshah path, Kathmandu P.O. Box 7626, Kathmandu, Nepal; +977 - 4254220; approval@nhrc.gov.np), ref: 353/2019 2. Approved 28/11/2018, University College London Research Ethics committee (Office of the Vice Provost Research, 2 Taviton Street, University College London, UK; +44 (0)20 7679 8717; ethics@ucl.ac.uk), ref: 14301/001 3. Approved 22/05/2019, London School of Hygiene and Tropical Medicine research ethics committee (Keppel Street, London, WC1E 7HT, UK; +44-(0)20 7636 8636; ethics@lshtm.ac.uk), ref: 16528",Nepal; Netherlands,,"Planned publication in a high-impact peer-reviewed journals to include the following: 1. Trial impact paper reporting on primary and secondary outcomes and pathways to impact outlined in the trial protocol. 2. Paper comparing aspects of dietary adequacy and intra-household food allocation between study arms. 3. A process evaluation paper evaluating possible pathways to impact from (mainly) quantitative data collected during trial implementation. 4. Other papers yet to be decided National- and provincial-level dissemination workshops will be held in Nepal with relevant policy makers, government officials, academics and other relevant stakeholders to inform them about the trial results. A policy brief will be prepared in English and Nepali and distributed widely at the dissemination events and elsewhere. Trial investigators will seek funds to present findings of the trial and of ancillary studies in national, regional and international conferences or workshops wherever possible. IPD sharing statement: The datasets generated during and/or analysed during the current study will be stored in a non-publicly available repository. Sharing of fully anonymised sharing participant-level data will begin 1 year after the publication of the main trial paper. As personal information (but no identifiers) will be included we will require users to apply to download the data from the UCL data repository, after review and approval of the application.",Stored in repository,,,Medical Research Council; Newton Fund,Health Research and Social Development forum (HERD),Missing GRID,http://dx.doi.org/10.13039/501100000265; http://dx.doi.org/10.13039/100010897,31/10/2023,01/11/2018,31/10/2022,13/06/2021,12/01/2022,14/06/2021,22/04/2021,Suspended,Suspended,Prospectively registered,Nil Known,Nil Known,Non-blinded parallel group two-arm cluster-randomized controlled trial,Prevention and treatment of anaemia in pregnant women Pregnancy and Childbirth,Pregnancy and Childbirth,,government organisationgovernment organisation,Research organisation,Cluster randomised trialCluster randomised trial,Community,Prevention,Mixed,,,Mixed,Mixed,Female,842,
291,ISRCTN48563324,Bathing adaptations in the homes of older adults 2,"CPMS 48800, IRAS 290805","Approved 09/03/2021, London - Camberwell St Giles Research Ethics Committee ( Ground Floor, Temple Quay House, 2 The Square, Bristol, BS1 6PN, UK; +44 (0)207 104 8340; camberwellstgiles.rec@hra.nhs.uk), ref: 21/LO/0044",United Kingdom,,"We anticipate producing four high-quality, high-impact peer reviewed papers. We will seek to publish the study protocol, the main RCT findings and cost effectiveness findings and an additional complementary health economics paper which will involve further exploration of EQ5D and ASCOT QALYs within one year after study completion. We will also publish the findings from the interviews and the survey of local authorities. We will co-produce a brief Plain English Summary of the study results with our PPI group and distribute this to participants at the end of the study. We will also produce the requisite NIHR SSCR academic and administrative reports, within the agreed timescales. IPD sharing statement: The datasets generated and/or analysed during the current study will be available upon reasonable request from the Chief Investigator (phillip.whitehead@northumbria.ac.uk) following completion of the trial and publication of trial results. Requests will be considered by the Trial Management Group on a case-by-case basis. Data will be made available for secondary analyses, and only anonymised data will be provided.",Available on request,,,National Institute for Health Research (NIHR); Grant Codes: 102645/T19-034/UN-P151,Northumbria University,grid.42629.3b,http://dx.doi.org/10.13039/501100000272,01/07/2024,01/12/2020,31/07/2023,01/06/2021,01/06/2022,22/04/2021,22/04/2021,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,Interventional randomized controlled trial,Bathing adaptations in the homes of older adults Not Applicable,Not Applicable,,government organisation,University/education,Randomised controlled trialRandomised controlled trial,Home,Quality of life,Behavioural,,,Patient,Adult,Both,360,
295,ISRCTN15851697,Helping alleviate the longer-term consequences of COVID-19,"CPMS 48890, IRAS 294861","Approved 07/04/2021, South Central - Berkshire Research Ethics Committee (Bristol REC Centre, Whitefriars, Level 3, Block B, Lewins Mead, Bristol, BS1 2NT, UK; +44 (0)207 104 8224, +44 (0)207 104 8270; berkshire.rec@hra.nhs.uk), REC ref: 21/SC/0121",United Kingdom,,"1. The protocol, Patient Information Sheet and other documents will be available on the study website https://www.heal-covid.net/ 2. The researchers intend to publish in fully open access peer-reviewed journals. It is intended that results be published as soon as possible when any treatment arm is removed, either due to clear efficacy or a clear indication that the treatment is no better than standard care. IPD sharing statement The datasets generated during and/or analysed during the current study are/will be available upon request. At the end of the trial, after the primary results have been published, all requests for access to trial data will be reviewed by the TMG and where at all possible access will be granted. Consent for data sharing for future research is included in the Patient Information Sheet & Consent form, and the trial website will be updated with details of any data sharing activities that take place.",Available on request,,,National Institute for Health Research,Cambridge University Hospitals NHS Foundation Trust,grid.24029.3d,http://dx.doi.org/10.13039/501100000272,31/01/2025,01/01/2021,31/01/2024,23/04/2021,31/01/2023,21/04/2021,21/04/2021,Ongoing,Recruiting,Prospectively registered,2021-001187-25,NCT04801940,"Randomized; Interventional; Design type: Treatment, Drug",COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,government organisation,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,"Apixaban, atorvastatin",Not Applicable,Patient,Adult,Both,1754,
317,ISRCTN18304314,Effect of convalescent plasma therapy on intensive care unit (ICU) deaths from COVID-19 in Suriname,Nil known,"Approved 03/06/2020, Suriname Ministry of Health’s Ethics Review Board (Henck Arronstraat 64, Paramaribo, Suriname; +597 477601; secretariaat.directeur@health.gov.sr), ref: IGAP02-482020",Suriname,,Expected online open access publication. IPD sharing statement: The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.,Other,,,Academic Hospital Paramaribo,Academic Hospital Paramaribo,grid.486089.b,,30/09/2021,10/04/2020,10/01/2021,03/06/2020,30/12/2020,14/04/2021,13/04/2021,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Open-label non-randomized prospective clinical trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,,Hospital/treatment centre,Non randomised studyNon randomised study,Hospitals,Treatment,Biological/Vaccine,Convalescent plasma,Not Applicable,Patient,Adult,Both,180,78.0
323,ISRCTN14396374,"A research study in Colombia, to build capacity in school mental health and to adapt an intervention called DIALOG+ for use in adolescents in post-conflict Colombia during the COVID-19 pandemic",ES/V013114/1,"1. Approved 20/11/2020, Comíté de Investigaciones y Ética Institucional, Facultad de Medicina, Pontificia Universidad Javeriana (Institutional Research and Ethics Committee, Faculty of Medicine, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Carrera 7 # 40-62, piso 2, Bogotá, Colombia; +57 (0)1 3208320 Ext 277; ciei@husi.org.co), ref: Adapting DIALOG+ and building capacities in schools to support mental wellbeing and resilience in post-conflict Colombia during the COVID-19 pandemic 2. Approved 09/04/2021, Queen Mary Ethics of Research Committee (Hazel Covill, Room W117, Finance Department, Queens' Building, Queen Mary University of London, Mile End Road, London, E1 4NS, UK; +44 (0)20 7882 7915; research-ethics@qmul.ac.uk), ref: QMERC20.226",Colombia,,"The researchers aim to publish at least three articles, on each of the work packages, in peer-reviewed journals by the end of December 2022. Results will also be presented at conferences and other academic meetings. The researchers intend to publish a protocol paper in due course, none is available now. No other documents are planned to be shared. IPD sharing statement After the publication of the main findings, the researchers will operate an open data policy, following the FAIR principles e.g. Findable, Accessible, Interoperable and Reusable. The anonymised datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request Carlos Gomez-Restrepo (cgomez@javeriana.edu.co). During the course of the study, data will be shared internally within the study using an online data collection platform called REDCap. The method for sharing the data externally (if required) will be decided in due course. Informed consent will be obtained from all participants involved in the study. All participants are assigned a patient ID at the point of enrolment and all subsequent data collected will be linked to this ID, without any link to identification data following Good Clinical Practice.",Available on request,,,"Newton Fund; Ministry of Science, Technology and Innovation (MInCiencias)",Queen Mary University of London,grid.4868.2,http://dx.doi.org/10.13039/100010897,31/12/2022,14/02/2021,31/12/2022,15/04/2021,30/09/2022,20/04/2021,12/04/2021,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,Exploratory cluster randomized controlled study,Mental health problems in the school environment Mental and Behavioural Disorders,Mental and Behavioural Disorders,,government organisation,University/education,Cluster randomised trialCluster randomised trial,Other,Treatment,Behavioural,,,Mixed,Mixed,Both,222,
340,ISRCTN17472338,"Advancing understanding of adolescent exposome exposure and methodology, intervention development, and translation for prevention strategies and policy","CPMS 47578, IRAS 289958","Approved 17/12/2020, Yorkshire & The Humber - Bradford Leeds Research Ethics Committee (NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle upon Tyne, NE2 4NQ, UK; +44 (0)2071048083; bradfordleeds.rec@hra.nhs.uk), REC ref: 20/YH/0315",United Kingdom,,"Planned publications in open access high-impact peer-reviewed journals. There are no additional files available at the moment. IPD sharing statement Contact should be made with Dan Mason (dan.mason@bthft.nhs.uk) for details on obtaining any of the data collected as part of WP1. Researchers will be required to submit an expression of interest and, if approved, sign a Collaboration Agreement. For WP7 the data are not expected to be made available because the data generated will be used to co-produce an intervention which will then be implemented and evaluated. Results for WP7 will be published.",Available on request,,,European Commission; Grant Codes: H2020-SC1-BHC-2018-2020,Bradford Royal Infirmary,grid.418447.a,http://dx.doi.org/10.13039/501100000780,31/12/2023,01/01/2020,31/12/2022,15/04/2021,31/12/2021,07/04/2021,07/04/2021,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,"Non-randomized; Both; Design type: Prevention, Psychological & Behavioural, Physical, Cohort study","Environmental hazards such as ambient air pollution, environmental tobacco smoke, water and food contaminants, noise, pesticides and ultraviolet light Not Applicable",Not Applicable,,government organisation,Hospital/treatment centre,Non randomised studyNon randomised study,Community,Other,Mixed,,,Mixed,Mixed,Both,296,
342,ISRCTN22331899,How effective is framing public service announcements using identity-based messaging in increasing the likelihood of compliance with COVID-19 guidelines?,2004499544,"Approved as exempt 29/04/2020, Indiana University Institutional Review Board (Human Research Protection Program, Office of Research Compliance, Indiana University, 2218 N. Dunn St., Bloomington, Indiana 47408; +1 (812) 856-4242; irb@iu.edu), ref: 2004499544",United States of America,,Planned publication in a peer-reviewed journal IPD sharing statement: The datasets generated during and/or analysed during the current study are/will be available upon request from Prof. Alan Dennis (ardennis@indiana.edu). The data will be available from 1/1/2021 for five years in Excel format for any researcher who requests a copy. All data are anonymous. All participants consented to participate.,Available on request,,,Indiana University Bloomington,Indiana University Bloomington,grid.411377.7,http://dx.doi.org/10.13039/100010178,01/07/2021,01/07/2020,01/08/2020,01/07/2020,01/08/2020,04/05/2021,07/04/2021,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Within- and between-subjects controlled randomized cross-sectional online study,Non-compliance with public service announcements regarding COVID-19 prevention Infections and Infestations Public health measures relating to COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,private sector organisation,University/education,Randomised cross over trialRandomised cross over trial,Internet,Prevention,Behavioural,,,Healthy volunteer,Adult,Both,300,300.0
354,ISRCTN14081521,"Can people with cystic fibrosis safely stop taking some of their nebulised treatments if they are established on the new modulator therapy, Kaftrio?","CPMS 48177, IRAS 293186","Approved 03/03/2021, London -London Bridge Research Ethics Committee (Skipton House, 80 London Road, London SE1 6LH; +44 (0)207 104 8019, +44 (0)207 104 8124; londonbridge.rec@hra.nhs.uk), ref: 21/LO/0080",United Kingdom,,"We have a detailed knowledge transfer plan following study end, that involves our PPI team and working closely with other research groups in the US. We will co-ordinate our findings to ensure clear messages are generated. Outcomes of the trial will be published in open-access peer-review journals, as standard. We will also work closely with the CF Trust to ensure people with CF and their healthcare teams have clear outcomes from the trial in order to best inform their future care pathways IPD sharing statement: CF STORM is a registry-based trial. The anonymised data will be available on the UK Cystic Fibrosis Registry through an application process.",Available on request,,,National Institute for Health Research,Alder Hey Children's NHS Foundation Trust,grid.417858.7,http://dx.doi.org/10.13039/501100000272,30/09/2024,30/09/2020,30/09/2023,01/04/2021,30/09/2022,01/04/2021,31/03/2021,Ongoing,Recruiting,Prospectively registered,2020-005864-77,Nil known,Open-label randomized controlled trial,"Cystic fibrosis Nutritional, Metabolic, Endocrine Cystic fibrosis","Nutritional, Metabolic, Endocrine",,government organisation,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,ivacaftor/tezacaftor/elexacaftor,Not Applicable,Patient,Adult,Both,764,
364,ISRCTN14391248,Combining influenza and COVID-19 vaccination (ComFluCOV) study,IRAS 297151,"Approved 17/03/2021, South Central - Berkshire Research Ethics Committee (Bristol REC centre, Whitefriars, Level 3, Block B, Lewins Mead, Bristol BS1 2NT; +44 (0)207 104 8224, +44 (0)207 104 8270; berkshire.rec@hra.nhs.uk), ref: 21/SC/0100",United Kingdom,,"Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The datasets generated during and/or analysed during the current study are/will be available upon request from Rajeka Lazarus (comFluCOV-trial@bristol.ac.uk). Anonymised trial data will only be made available for sharing outside the ComCOV studies group after publication of the main results of the trial. Thereafter, individual participant data will be made available for secondary research, conditional on assurance from the secondary researcher that the proposed use of the data is compliant with the MRC Policy on Data Sharing regarding scientific quality, ethical requirements, and value for money. A minimum requirement with respect to scientific quality will be a publicly available pre-specified protocol describing the purpose, methods, and analysis of the secondary research, e.g., a protocol for a Cochrane systematic review.",Available on request,,,Vaccine Taskforce (VTF); National Institute for Health Research,University Hospitals Bristol NHS Foundation Trust,grid.410421.2,http://dx.doi.org/10.13039/501100000272,31/08/2022,01/03/2021,31/08/2021,29/03/2021,30/05/2021,07/05/2021,30/03/2021,Ongoing,No longer recruiting,Retrospectively registered,2021-001124-18,Nil known,Multicentre triple-blind parallel-group randomized placebo-controlled trial,Adults receiving the influenza (flu) vaccine who may also need COVID-19 booster vaccines Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,government organisation,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Other,Prevention,Drug,"Influenza vaccines (Flucelvax (QIV), FluAd (MF59) & Flublok (QIVr)) COVID-19 vaccines (ChadOx1-nCOV-19 (AstraZeneca/Oxford) vaccine & 6.1.2 BNT162b2 (Pfizer BioNTech) vaccine)",Phase IV,Healthy volunteer,Adult,Both,756,
376,ISRCTN27841311,Comparing COVID-19 vaccine schedule combinations  – stage 2,OVG 2021/01,Not provided at time of registration,United Kingdom,,1. The protocol can be found at https://comcovstudy.org.uk/ 2. Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The current data-sharing plans for this study are unknown and will be available at a later date.,To be made available at a later date,,,National Institute for Health Research; UK Vaccine Task Force; Collaboration for Epidemic Preparedness,University of Oxford,grid.4991.5,http://dx.doi.org/10.13039/501100000272,01/09/2023,02/03/2020,01/09/2022,19/04/2021,21/05/2021,24/06/2021,26/03/2021,Ongoing,No longer recruiting,Prospectively registered,2021-001275-16,Nil known,Single-blind randomized study,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,government organisation,University/education,Randomised controlled trialRandomised controlled trial,Other,Prevention,Biological/Vaccine,"AstraZeneca COVID-19 vaccine AZD1222 (ChAdOx1 nCOV-19), Pfizer BioNTech (BNT162b2), COVID-19 Vaccine Moderna, Novavax, NVX-CoV2373",Phase II,Healthy volunteer,Adult,Both,1050,
384,ISRCTN72605600,What messaging is effective in recruiting schools to take up tutoring? A randomised controlled trial of email messages to schools.,Nil known,"The study does not require ethics approval. The study will be conducted in accordance with NFER’s Code of Practice, available at: https://www.nfer.ac.uk/media/1166/codeofpractice.pdf. School key contacts/headteachers will be informed of the study in the recruitment emails and will be able to view full details about the study in a link to the Privacy Notice the embedded in the recruitment emails. The Privacy Notice sets out what data is being gathered as part of the trial and gives school contacts the opportunity to withdraw from data processing if they have objections. Key school contacts who reply to the recruitment emails (without withdrawing from data processing) will therefore provide the ethical agreement for participation in the trial.",United Kingdom,,"A report of the study findings will be published on the Education Endowment Foundation and National Foundation for Educational Research websites. IPD sharing statement: The datasets generated during and/or analysed during the current study will be stored in a publically available repository. One month after the publication of the evaluation report, de-identified data (no individual’s names, contact details or job roles) and analysis code will be submitted to the UK Data Archive for storage, as part of transparent analysis and reporting of RCTs. The data will include the school name. No individuals will be identifiable in the dataset.",Stored in repository,,,Education Endowment Foundation,Education Endowment Foundation,grid.484108.1,http://dx.doi.org/10.13039/100012343,28/07/2021,13/01/2021,28/06/2021,03/02/2021,23/03/2021,06/04/2021,24/03/2021,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil Known,Interventional randomized controlled trial,"To explore what works in engaging schools/senior leaders to sign up to catch-up tutoring support for their students, which provides subsidised tuition to supplement high-quality classroom teaching as a way of supporting children’s learning in response to the Covid-19 pandemic. Not Applicable",Not Applicable,,private sector organisation,Charity,Randomised controlled trialRandomised controlled trial,Schools,Other,Other,,,Other,Other,Both,2000,
387,ISRCTN16393332,Remote monitoring of blood pressure in patients with high blood pressure during the COVID-19 pandemic,"CPMS 47197, IRAS 283209","Approved 29/06/2020, London - Dulwich Research Ethics Committee (Health Research Authority, Skipton House, 80 London Road, London, SE1 6LH, UK; +44 (0)20 7972 2545; hra.approval@nhs.net), 20/HRA/2988",United Kingdom,,"Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The datasets generated during and/or analysed during the current study are not expected to be made available. As per current protocol, dataset will be available for the The CI, PIs, study team, funders Closed Loop Medicine Ltd. and TMG members will have access to the final dataset from the eCRF for study analysis and reporting. The TSC will have access to interim data for safety analysis. All relevant data from this study will be submitted to peer review journals for publication following the termination of the study in line with sponsor and trust publication policy. The clinical study results will be accessible via EudraCT within one year of end of trial definition being met and Clinical trials.gov.",Not expected to be available,,,Innovate UK; Grant Codes: 105319; Closed Loop Medicine Ltd,Queen Mary University of London,grid.4868.2,http://dx.doi.org/10.13039/501100006041,01/06/2022,01/06/2020,31/07/2021,26/10/2020,30/05/2021,24/03/2021,24/03/2021,Ongoing,No longer recruiting,Retrospectively registered,2020-002494-10,NCT04559074,Interventional non randomized with observational sub study,High blood pressure Circulatory System Hypertension,Circulatory System,,government organisation,University/education,Non randomised studyNon randomised study,Community,Treatment,Drug,amlodipine,Not Applicable,Patient,Adult,Both,1000,
393,ISRCTN21085622,Assessing the safety and effectiveness of sofosbuvir plus daclatasvir or ravidasvir in Egyptian adults with COVID-19,PHA-SDR-002,"1. Approved 20/04/2020, Menoufia University National Liver Institute IRB (Shebin Elkom, Menoufia, Egypt, NLI IRB 00003413; +20 (0)482222740; gamalelsaidmousa@gmail.com), ref: NLI IRB 00003413 2. Approved 05/08/2020, Research Ethics Committee, Egyptian Ministry of Health (Saad Zaglool Street, Kasr Elainy, Cairo, Egypt; +202 27946369; mohp.rec@gmail.com), ref: IRB 0000687",Egypt,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.,Available on request,,,European Egyptian Pharmaceutical Industries (EEPI),European Egyptian Pharmaceutical Industries (EEPI),TESTING,,01/05/2021,15/03/2020,10/03/2021,29/09/2020,29/12/2021,22/03/2021,23/03/2021,Completed,Recruiting,Retrospectively registered,Nil known,Nil known,Multicenter randomized open-label prospective interventional controlled parallel-group study,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,Industry,Randomised parallel trialRandomised parallel trial,Hospitals,Treatment,Drug,"Sofosbuvir, daclatasvir, ravidasvir",Phase II/III,Patient,Adult,Both,120,
396,ISRCTN70307341,A study to test a package of support to help women who have stopped smoking while pregnant to stay smoke-free after giving birth,"CPMS 48117, IRAS 291746","Approved 12/03/2021, North West – Preston Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Steet, Manchester M1 3DZ, UK; +44 (0)207 104 8206; preston.rec@hra.nhs.uk), ref: 21/NW/0017",United Kingdom,,1. The researchers plan to publish the protocol in the future and will provide the link once this has been done. 2. Planned publication in a high-impact peer-reviewed journal IPD sharing statement The data-sharing plans for the current study are unknown and will be made available at a later date,To be made available at a later date,,,"NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR129074",University of East Anglia,grid.8273.e,,03/12/2024,01/10/2020,03/12/2023,01/04/2021,31/03/2022,23/03/2021,23/03/2021,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,Interventional randomized controlled trial,Pre and postnatal support for women who have stopped smoking in pregnancy Not Applicable,Not Applicable,,,University/education,Randomised controlled trialRandomised controlled trial,Home,Quality of life,Behavioural,,,Patient,Adult,Female,880,
397,ISRCTN17441953,Ultrasound visual biofeedback versus standard treatment for children with cleft lip and palate,2.0,Pending,United Kingdom,,"Planned publication in high impact journal IPD sharing statement: The datasets generated during and/or analysed during the current study will be stored in a publically available repository, the University of Strathclyde's data sharing depository, PURE https://pureportal.strath.ac.uk/ . With explicit permission from patients and their carers we will share anonymised raw ultrasound and audio data indefinitely. Data will contain some natural speech/voice samples and it is possible that participant's voices could be recognised, therefore consent to share will be optional. Data will be deposited within 1 year of the end of the project.",Stored in repository,,,"Chief Scientist Office, Scottish Government Health and Social Care Directorate",University of Strathclyde,grid.11984.35,http://dx.doi.org/10.13039/100014589,01/06/2024,01/07/2019,31/05/2023,01/08/2021,31/03/2023,22/03/2021,22/03/2021,Ongoing,Not yet recruiting,Prospectively registered,Nil known,Nil known,Single centre pilot/feasibility randomised control trial,Treatment of speech disorders associated with cleft lip and palate Neonatal Diseases Cleft lip and cleft palate,Neonatal Diseases,,government organisation,University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Behavioural,,,Patient,Child,Both,40,
415,ISRCTN17846723,A web-based referral service to facilitate rapid and direct access to mental health care for youth,CIHR FRN 143555,"Approved 17/09/2020, CHUM Research Ethics Committee (Tour Viger, 900, Saint Denis Street, Montreal, Quebec, H2X 0A9, Canada; +1 (514) 890 8000 ext. 14485; ethique.recherche.chum@ssss.gouv.qc.ca), ref: MP-02-2021-9098",Canada,,The manuscript of the study protocol is in preparation for peer review submission. Planned publications in open access peer-reviewed scientific journals and presentations at meetings and peer-reviewed scientific conferences pertinent to mental health and service delivery. IPD sharing statement The data-sharing plans for the current study are unknown and will be made available at a later date.,To be made available at a later date,,,Canadian Institutes of Health Research; Graham Boeckh Foundation,Centre Hospitalier de l’Université de Montréal,grid.410559.c,http://dx.doi.org/10.13039/501100000024,30/09/2023,31/01/2016,31/03/2023,16/03/2021,16/03/2023,24/03/2021,16/03/2021,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,"Mixed-methods convergent QUAN-QUAL multiple-case study methodology, including exploratory analyses based on a quasi-experimental interrupted time-series design",Web-based referral to mental health services for youth Mental and Behavioural Disorders,Mental and Behavioural Disorders,,government organisation,Hospital/treatment centre,Non randomised studyNon randomised study,Internet,Other,Other,,,Mixed,Mixed,Both,180,
422,ISRCTN46897021,"An exploratory study in primary care to test the feasibility of an intervention called DIALOG+, designed to improve quality of life for people in primary care with poor mental and physical health",IRAS 294469,Not provided at time of registration,United Kingdom,,"The researcher intends to publish the quantitative and qualitative findings from this study by 2022. Findings will also be presented at relevant conferences and shared on social media. Finally, the study will form a chapter in the researcher’s PhD thesis. No additional documents will be available. IPD sharing statement The data-sharing plans for the current study are unknown and will be made available at a later date.",To be made available at a later date,,,Barts Charity,Queen Mary University of London,grid.4868.2,http://dx.doi.org/10.13039/100015652,31/12/2022,01/01/2021,31/12/2021,01/10/2021,31/12/2021,08/06/2021,15/03/2021,Ongoing,Not yet recruiting,Prospectively registered,Nil known,Nil known,Multi-centre interventional mixed-methods study,Improving quality of life for patients with mental health and/or long-term physical health problems Not Applicable,Not Applicable,,private sector organisation,University/education,Non randomised studyNon randomised study,GP practices,Quality of life,Behavioural,,,Mixed,Adult,Both,10,
435,ISRCTN15328700,Developing and evaluating a diabetes self-management intervention for people with severe mental illness,"IRAS 279019, CPMS 48674","Approved 06/04/2021, Leeds West Research Ethics Committee (NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle upon Tyne, NE2 4NQ, UK; +44 (0)207 1048 088; leedswest.rec@hra.nhs.uk), REC ref: 21/YH/0059",United Kingdom,,"Planned publication in a high-impact peer-reviewed journal. Further dissemination activities will include social media, blogs, and relevant conference presentations at regional, national, and international events. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date.",To be made available at a later date,,,Programme Grants for Applied Research,University of York; Bradford District Care NHS Foundation Trust,grid.5685.e; grid.498142.2,http://dx.doi.org/10.13039/501100007602,01/02/2023,01/12/2019,28/02/2022,01/07/2021,31/10/2021,16/06/2021,12/03/2021,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,Single-group before and after feasibility study with exploratory economic and mixed methods process evaluations,"Type 2 diabetes in people with severe mental illness Nutritional, Metabolic, Endocrine Type 2 diabetes mellitus","Nutritional, Metabolic, Endocrine",,government organisation,University/education; Hospital/treatment centre,Non randomised studyNon randomised study,Hospitals,Treatment,Behavioural,,,Patient,Adult,Both,30,
438,ISRCTN16806663,A clinical trial to evaluate the effects of inhaled nitric oxide gas among COVID-19 patients with pneumonia,Nil known,"Approved 08/05/2020, Institutional Ethics Committee Amrita Institute of Medical Sciences (AIMS, Ponekkara, Kochi, Edappally, Ernakulam, Kerala 682041, India; +91 (0)484 2858750; https://www.amritahospitals.org/), ref: IEC/AIMS-2020/CARDANES-044",India,,Planned for publication in a high-impact peer-reviewed journal. The full trial record (methods statistical plan and results) will be uploaded post-completion either as part of the trial record or on a registry of peer prints such as medrxiv.org. IPD sharing statement: The data sharing plans for the current study are unknown and will be made available at a later date,To be made available at a later date,,,Amrita School of Biotechnology,Amrita Institute of Medical Sciences and Research Centre,grid.427788.6,,05/02/2022,10/06/2020,05/02/2021,20/09/2020,12/12/2020,19/03/2021,11/03/2021,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Prospective phase II open-label randomized controlled feasibility trial,Adult COVID-19 pneumonia patients with hypoxic respiratory failure Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Drug,Nitric Oxide gas,Phase II,Patient,Adult,Both,25,29.0
444,ISRCTN51046126,Feasibility of providing additional oxygen in patients with resistant high blood pressure and obstructive sleep apnoea,"CPMS 48021, IRAS 279286","Approved 02/02/2021, East of England - Essex Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 104 8106; essex.rec@hra.nhs.uk) ref: 21/EE/0010",United Kingdom,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date.,To be made available at a later date,,,Academy of Medical Sciences; Grant Codes: SGL022\1063,University of Oxford,grid.4991.5,http://dx.doi.org/10.13039/501100000691,01/04/2023,02/02/2021,30/04/2022,30/04/2021,01/04/2022,06/04/2021,11/03/2021,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,Interventional non-randomized,Obstructive sleep apnoea in patients with resistant hypertension Nervous System Diseases Sleep apnoea,Nervous System Diseases,,private sector organisation,University/education,Non randomised studyNon randomised study,Home,Treatment,Other,,,Patient,Adult,Both,20,
463,ISRCTN39426207,High-intensity functional interval training in heart failure,Nil known,"Approved 31/05/2018, Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec research ethics committee (1991, boulevard du Carmel, Trois-Rivières, G8Z 3R9, Canada; +1 819-372-3133 poste 32303; ciusssmcq_bureau_integre_de_lethique@ssss.gouv.qc.ca), ref: CER-18-248-07.01",Canada,,Planned publication in a high-impact peer-reviewed journal. Planned publication of protocol in 2021. IPD sharing statement: The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication,Other,,,Novartis,Université du Québec à Trois-Rivières,grid.265703.5,http://dx.doi.org/10.13039/100004336,30/01/2023,10/01/2018,30/01/2023,01/06/2018,30/12/2021,11/03/2021,04/03/2021,Ongoing,Recruiting,Retrospectively registered,Nil known,Nil known,Interventional randomized controlled trial,Secondary prevention of heart failure with a reduced ejection fraction Circulatory System Left ventricular failure,Circulatory System,,government organisation,University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Quality of life,Behavioural,,,Patient,Adult,Both,30,
487,ISRCTN16205138,Effectiveness of short-term audio mindfulness in the Chinese community: a pilot study,Nil known,"Approved 18/02/2021, Research Ethics Committee of Hong Kong Baptist University (Graduate School, Hong Kong Baptist University, Kowloon Tong, Hong Kong; no telephone number provided; hkbu_rec@hkbu.edu.hk), ref: REC/20-21/0270",China,,Planned publication in a high-impact peer-reviewed journal which would share participant-level data as required by the WHO and ICMJE. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date.,To be made available at a later date,,,Investigator initiated and funded,Hong Kong Baptist University,grid.221309.b,,01/09/2022,03/10/2020,01/09/2021,15/03/2021,01/05/2021,18/05/2021,26/02/2021,Ongoing,No longer recruiting,Prospectively registered,Nil known,Nil known,Multicenter interventional non-blinded randomized controlled trial,Improvement of mental health in Chinese community-dwelling people during COVID-19 period Mental and Behavioural Disorders,Mental and Behavioural Disorders,,,University/education,Randomised controlled trialRandomised controlled trial,Internet,Quality of life,Behavioural,,,Healthy volunteer,Adult,Both,140,100.0
504,ISRCTN15615992,Neuropsychological evaluation and rehabilitation in multiple sclerosis – qualitative case study,"CPMS 44712, IRAS 276903","Approved 20/04/2020, North West – Greater Manchester West Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)207 104 8384, +44 (0)207 104 8068, +44 (0)207 104 8328; gmwest.rec@hra.nhs.uk), REC ref: 20/NW/0081",United Kingdom,,Planned publication in a high-impact peer-reviewed journal. Additional files not yet available. IPD sharing statement The data-sharing plans for the current study are unknown and will be made available at a later date.,To be made available at a later date,,,National Institute for Health Research - Programme Grant for Applied Research (Ref. No.: RP-PG-0218-20002),Nottinghamshire Healthcare NHS Foundation Trust,grid.439378.2,http://dx.doi.org/10.13039/501100000272,28/02/2023,20/07/2017,28/02/2022,01/05/2021,31/12/2021,23/02/2021,23/02/2021,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,"Non-randomized; Both Interventional and Observational; Design type: Treatment, Process of Care, Psychological & Behavioural, Complex Intervention, Management of Care, Rehabilitation, Validation of investigation /therapeutic procedures",Multiple sclerosis Nervous System Diseases Multiple sclerosis,Nervous System Diseases,,government organisation,Hospital/treatment centre,Non randomised studyNon randomised study,Hospitals,Treatment,Behavioural,,,Mixed,Adult,Both,35,
525,ISRCTN11204126,Contact tracing in care homes using digital technology for improving infection control including COVID-19,"CPMS 47853, IRAS 292204","Approved 23/11/2020, Yorkshire and Humber – Bradford Leeds SCREC (NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle upon Tyne, NE2 4NQ, UK; +44 (0)2071048083; bradfordleeds.rec@hra.nhs.uk), REC ref: 20/YH/0326",United Kingdom,,"1. Protocol to be available on the study website: https://ctru.leeds.ac.uk/contact 2. As this is feasibility work the researchers have yet to determine if protocol and SAP papers will be published – main trial documents will be published 3. Planned publication in a high-impact peer-reviewed journal by January 2024 IPD sharing statement Data supporting this work are available on reasonable request. All requests will be reviewed by relevant stakeholders, based on the principles of a controlled access approach. Requests to access data should be made to CTRU-DataAccess@leeds.ac.uk in the first instance.",Available on request,,,"NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR132197",University of Leeds,grid.9909.9,,01/01/2024,01/10/2020,31/01/2023,05/01/2021,01/12/2021,17/02/2021,17/02/2021,Ongoing,Recruiting,Retrospectively registered,Nil known,Nil known,"Both; Design type: Prevention, Process of Care, Device, Complex Intervention, Management of Care, Active Monitoring, Qualitative",COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,University/education,Non randomised studyNon randomised study,Other,Prevention,Device,,Not Applicable,Mixed,Mixed,Both,400,
557,ISRCTN15638344,A phase II study of a candidate COVID-19 vaccine in children (COV006),"COV006, IRAS 293182","Approved 10/02/2021, Berkshire Research Ethics Committee (Easthampstead Baptist Church, South Hill Road, Bracknell, RG12 7NS, UK; berkshire.rec@hra.nhs.uk, +44 (0)207 104 8224), ref: 21/SC/0054",United Kingdom,,There are no plans currently to have any additional documents be available. Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date.,To be made available at a later date,,,National Institute for Health Research; AstraZeneca UK,University of Oxford,grid.4991.5,http://dx.doi.org/10.13039/501100000272,01/09/2023,02/03/2020,30/09/2022,15/02/2021,17/04/2021,09/06/2021,11/02/2021,Ongoing,No longer recruiting,Prospectively registered,2020-005765-13,Nil known,Single-blinded randomized controlled multi-centre,Prevention of COVID-19 infection in children Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,government organisation,University/education,Randomised controlled trialRandomised controlled trial,Other,Prevention,Biological/Vaccine,"ChAdOx1 nCoV-19, Meningococcal Group B vaccine (Bexsero®)",Phase II,Healthy volunteer,Child,Both,300,
565,ISRCTN85874083,Comparing cotrimoxazole to standard care for the treatment of severe coronavirus (COVID-19) infection in hospitalised patients,CTRI/2021/02/031012,"1. Approved 09/01/2021, Institutional Ethics Committee, Medical College Kolkata (88, College St, Calcutta Medical College, College Square, Kolkata, West Bengal 700073; +919433084372; no email address available), ref: MC/KOL/IEC/NON-SPON/863/01/2021 2. Approved 14/01/2021, Clinical Research Ethics Committee (Calcutta School of Tropical Medicine, 108 Chitta Ranjan Avenue, Kolkata 700073; +919433349332; smnaser2012@gmail.com), ref: CREC-STM/2020-AS-18",India,,Planned publication in a high-impact peer-reviewed journal IPD sharing statement: The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication,Other,,,"Department of Health and Family Welfare, Government of West Bengal","School of Tropical Medicine, Kolkata",Missing GRID,http://dx.doi.org/10.13039/501100013952,01/10/2021,01/10/2020,01/10/2021,15/02/2021,31/08/2021,13/05/2021,09/02/2021,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,Single-centre randomized controlled trial,Hospitalized patients with severe COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,government organisation,Government,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Drug,cotrimoxazole,Not Applicable,Patient,Adult,Both,200,
571,ISRCTN11203922,Neuropsychological evaluation and rehabilitation in multiple sclerosis – feasibility study,"CPMS 47750, IRAS 287115","Approved 13/01/2021, North West – Greater Manchester West Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)2071048384, +44 (0)207 104 8068; gmwest.rec@hra.nhs.uk), REC ref: 20/NW/0454",United Kingdom,,Planned publication in a high-impact peer-reviewed journal. Additional files not yet available. IPD sharing statement The data-sharing plans for the current study are unknown and will be made available at a later date.,To be made available at a later date,,,National Institute for Health Research (NIHR) - Programme Grant for Applied Research (Ref. No.: RP-PG-0218-20002),Nottinghamshire Healthcare NHS Foundation Trust,grid.439378.2,http://dx.doi.org/10.13039/501100000272,31/05/2023,20/07/2017,31/10/2022,01/09/2021,31/08/2022,19/05/2021,09/02/2021,Ongoing,Not yet recruiting,Prospectively registered,Nil known,Nil known,"Randomized; Both Interventional and Observational; Design type: Treatment, Screening, Process of Care, Psychological & Behavioural, Complex Intervention, Management of Care, Validation of investigation /therapeutic procedures",Multiple sclerosis Nervous System Diseases Multiple sclerosis,Nervous System Diseases,,government organisation,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Behavioural,,,Mixed,Adult,Both,2545,
598,ISRCTN85436698,Phase III trial of inhaled SNG001 compared to placebo for the treatment of patients hospitalised due to moderate COVID-19,"SG018, IRAS 290965, CPMS 47416, UPH","Approved 09/11/2020, London - Riverside Research Ethics Committee (Level 3 Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT, UK; +44 (0)207 104 8340; riverside.rec@hra.nhs.uk), REC ref: 20/HRA/5234",Argentina; Belgium; Brazil; Colombia; France; Germany; India; Israel; Italy; Mexico; Netherlands; Portugal; Romania; Serbia; Spain; United Kingdom; United States of America,,Planned publication in a high-impact peer-reviewed journal IPD sharing statement The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication,Other,,,Synairgen Research Ltd,Synairgen Research Ltd,Missing GRID,,01/03/2022,13/08/2020,01/09/2021,12/01/2021,01/06/2021,25/03/2021,03/02/2021,Ongoing,No longer recruiting,Retrospectively registered,2020-004743-83,NCT04732949,Multi-centre interventional double-blind placebo-controlled randomized clinical trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,Industry,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,SNG001 (inhaled interferon-β),Phase III,Patient,Adult,Both,610,
599,ISRCTN69254139,Comparing coronavirus (COVID-19) vaccine schedule combinations,"CPMS 48289, IRAS 291055, OVG2020/03","Approved 20/01/2021, South Central - Berkshire Research Ethics Committee (Bristol REC Centre, Whitefriars, Level 3, Block B, Lewins Mead, Bristol, BS1 2NT), ref: 21/SC/0022",United Kingdom,,"Publication policy: The Investigators will be involved in reviewing drafts of the manuscripts, abstracts, press releases, and any other publications arising from the study. Data from the study may also be used as part of a thesis for a PhD or MD. IPD sharing statement: The data sharing plans for the current study are unknown and will be made available at a later date",To be made available at a later date,,2021 early results of reactogenicity data in https://doi.org/10.1016/S0140-6736(21)01115-6 (added 18/05/2021),UK Vaccine Task Force; National Institute for Health Research,University of Oxford,grid.4991.5,http://dx.doi.org/10.13039/501100000272,31/08/2021,01/10/2020,05/11/2022,08/02/2021,28/02/2021,24/06/2021,03/02/2021,Ongoing,No longer recruiting,Prospectively registered,2020-005085-33,Nil known,Multi-centre single-blind phase II randomized parallel study,COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,government organisation,University/education,Randomised parallel trialRandomised parallel trial,Hospitals,Prevention,Biological/Vaccine,"ChAdOx1 nCOV-19 vaccine, tozinameran vaccine",Phase II,All,Adult,Both,820,
659,ISRCTN13593711,A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia,"WA42380, IRAS 282099","Approved 30/03/2020, Advarra (6940 Columbia Gateway Drive, Columbia, MD, 21046, USA; +1 4108842900; no email provided), ref: none provided",Canada; Denmark; France; Germany; Italy; Netherlands; Spain; United Kingdom; United States of America,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date,To be made available at a later date,,2020 non-peer-reviewed results in preprint https://doi.org/10.1101/2020.08.27.20183442 (added 21/01/2021) 2021 results in https://doi.org/10.1056/NEJMoa2028700 (added 17/03/2021),Genentech; Biomedical Advanced Research and Development Authority,Genentech,Missing GRID,http://dx.doi.org/10.13039/100004328; http://dx.doi.org/10.13039/100012399,01/07/2021,10/03/2020,28/07/2020,03/04/2020,28/05/2020,17/03/2021,21/01/2021,Completed,No longer recruiting,Retrospectively registered,2020-001154-22,NCT04320615,Randomized double-blind placebo-controlled multicenter study,COVID-19 (SARS-CoV-2 infection) pneumonia Infections and Infestations,Infections and Infestations,,private sector organisationgovernment organisation,Industry,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,Tocilizumab,Not Applicable,Patient,Mixed,Both,450,452.0
660,ISRCTN17941313,Determining trustworthiness and safety of remote consulting during the COVID-19 pandemic in primary healthcare for chronic disease populations in Nigeria and Tanzania,Grant Ref: EP/V028936/1,"Approved 11/11/2020, King's College London Research Ethics Board (King's College London, Franklin Wilkins Building, 5.9 Waterloo Bridge Wing, Waterloo Road, London SE1 9NH; +44 (0)20 7848 4020/4070/4077; rec@kcl.ac.uk) ref: HR-20/21-21006",Nigeria; Tanzania,,"Planned publication in open access peer review journals, presentation at conferences and engagement with policy makers in partner countries and the UK including governments, NGOs, and digital health and telecommunications companies. We will undertake stakeholder activities within each country building on our existing stakeholder communities and engaging with the local facilities to interpret and extend the impact of our findings. IPD sharing statement: The data sharing plans for the current study are unknown and will be made available at a later date.",To be made available at a later date,,,UK Research and Innovation; Global Challenges Research Fund; Newton Fund,King's College London,grid.13097.3c,http://dx.doi.org/10.13039/100014013; http://dx.doi.org/10.13039/100016270; http://dx.doi.org/10.13039/100010897,01/11/2022,21/08/2020,20/02/2022,01/02/2020,01/12/2021,20/01/2021,20/01/2021,Ongoing,Recruiting,Retrospectively registered,Nil known,Nil known,Multi-centre international stepped-wedge cluster randomized trial,"Chronic disease, type 2 diabetes, hypertension, chronic obstructive pulmonary disease, coronary heart disease Not Applicable",Not Applicable,,private sector organisationgovernment organisationgovernment organisation,University/education,Cluster randomised trialCluster randomised trial,GP practices,Treatment,Behavioural,,,Patient,Adult,Both,800,
687,ISRCTN51124684,Can drinking beetroot juice prevent and reduce the severity of winter viral infections in residential and nursing homes?,"IRAS 288542, Version 2.0 19/10/20","Approved 25/11/2010, West Midlands - Coventry & Warwickshire Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS; +44 (0)207 104 8009; coventryandwarwick.rec@hra.nhs.uk), ref: 20/WM/0278",United Kingdom,,Trial results will be published in a peer-reviewed academic journal. Reporting will be in compliance with CONSORT recommendations. The focus of that article will be to discuss the feasibility of using beetroot juice in care homes and the proof of concept. Findings will also be presented at relevant conferences. The study protocol is available at https://srtoke.nottingham.ac.uk/beet-winter/. IPD sharing statement: The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.,Other,,,NIHR Nottingham Biomedical Research Centre (BRC); Philip Bath NIHR Senior Investigator Award,University of Nottingham,grid.4563.4,,30/09/2022,01/09/2020,31/08/2022,01/05/2021,31/05/2022,11/05/2021,13/01/2021,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,Prospective phase II cluster-randomized double-blind placebo-controlled trial assessing feasibility and proof of principle,Winter respiratory viral infections in care home residents Respiratory,Respiratory,,,University/education,Randomised controlled trialRandomised controlled trial,Other,Prevention,Supplement,,,Other,Senior,Both,416,
688,ISRCTN37254291,"In the general population, do specific forms of COVID-19 vaccine information, above simple information that they are safe and effective, increase willingness to be vaccinated?",Protocol 1.0,"Approved 08/01/2021, University of Oxford Central University Research Ethics Committee (Research Services, University of Oxford, Wellington Square, Oxford, OX1 2JD, UK; +44 (0)1865 616577; ethics@medsci.ox.ac.uk), ref: R74001/RE001",United Kingdom,,The researchers plan to publish the results in a peer-reviewed journal. Additional documents will be available directly from the research team. IPD sharing statement Anonymised data will be available for reasonable requests. These requests can be made to Prof. Daniel Freeman (daniel.freeman@psych.ox.ac.uk) after the publication of the main report from the trial. The data will be available for a minimum of 3 years.,Available on request,,2021 results in https://pubmed.ncbi.nlm.nih.gov/33991482/ (added 17/05/2021),NIHR Oxford Biomedical Research Centre; NIHR Oxford Health Biomedical Research Centre,University of Oxford,grid.4991.5,http://dx.doi.org/10.13039/501100013373,01/03/2021,13/12/2020,01/02/2021,18/01/2021,01/02/2021,17/05/2021,13/01/2021,Completed,No longer recruiting,Prospectively registered,Nil known,Nil known,Single-blind parallel-group randomized controlled design with planned mediation and moderation tests,COVID-19 (SARS-CoV-2 infection) vaccine hesitancy Infections and Infestations,Infections and Infestations,,private sector organisation,University/education,Randomised parallel trialRandomised parallel trial,Community,Prevention,Other,,,Healthy volunteer,Adult,Both,18500,15014.0
697,ISRCTN18107122,Participatory digital interventions for front-line staff during the coronavirus (COVID-19) pandemic,"IRAS 284547, v5 04/06/2020","Approved 24/06/2020, South West - Frenchay REC (Level 3, Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT; +44 (0)207 104 8028; frenchay.rec@hra.nhs.uk), ref: 20/SW/0098",United Kingdom,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The datasets generated during and/or analysed during the current study will be stored in a non-publically available repository (https://myuhi.sharepoint.com/sites/eo-crhwb/Psychological_Resilience/SRUC%20Shared%20Documents/SitePages/Home.aspx). The data is stored securely in the university’s SharePoint site. Only anonymised data will be shared with statisticians. Only the research team will have access to raw data and the data will be kept only for the duration of the data analyses.,Not expected to be available,,,"Chief Scientist Office, Scottish Government Health and Social Care Directorate",NHS Highland; University of the Highlands and Islands,grid.428629.3; grid.23378.3d,http://dx.doi.org/10.13039/100014589,01/11/2021,26/03/2020,14/10/2020,15/06/2020,14/09/2020,11/01/2021,11/01/2021,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,A single centre randomized controlled trial with a cross sectional survey,Mental wellbeing of NHS staff during the COVID-19 pandemic Mental and Behavioural Disorders,Mental and Behavioural Disorders,,government organisation,Hospital/treatment centre; University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Quality of life,Behavioural,,,Health professional,Adult,Both,180,180.0
704,ISRCTN85787008,Effect of heartfulness meditation on loneliness and sleep in physicians and advance practice providers,IRB number 1568071-3,"Approved 06/07/2020, Wellspan IRB (1001, S George St, York, Pennsylvania - 17403, USA; +1 717 8512223; irb@wellspan.org), ref: 1568071-3",United States of America,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date,To be made available at a later date,,2021 results in https://pubmed.ncbi.nlm.nih.gov/33682592/ (added 09/03/2021),Investigator initiated and funded,WellSpan Health,grid.430889.e,,30/09/2021,20/02/2020,12/10/2020,21/07/2020,10/08/2020,09/03/2021,08/01/2021,Completed,No longer recruiting,Retrospectively registered,Nil Known,Nil Known,Single institutional randomized controlled prospective study,Loneliness and sleep in physicians and advance practice providers Not Applicable,Not Applicable,,,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Quality of life,Behavioural,,,Health professional,Adult,Both,200,155.0
725,ISRCTN14037053,Dendritic cell vaccine to prevent COVID-19,"UTN U1111-1263-0568, CL-COV-P02-ID","Approved 26/11/2020, Health Research Ethics Committee Central Army Hospital RSPAD Gatot Soebroto (Jl. Abdul Rahman Saleh No. 24 Jakarta Pusat 10410; +6221-3441008; kepkrspad@gmail.com), ref: 06/XI/KEPK/2020",Indonesia,,"Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Data will become available beginning 9 months and ending 36 months following article publication. Individual participant data that underlie the results reported in this article will be shared after deidentification (text, tables, figures, and appendices). Data will be shared with researchers who provide a methodologically sound proposal in order to achieve the aims in the approved proposal. Proposals should be directed to muhammad.karyana@kemkes.go.id. To gain access, data requestors will need to sign a data access agreement",Available on request,,,"Ministry of Health, Republic of Indonesia",Ministry of Health,grid.419858.9,,31/12/2022,26/11/2020,31/01/2022,07/12/2020,31/01/2021,30/12/2020,31/12/2020,Ongoing,No longer recruiting,Retrospectively registered,Nil known,NCT04685603,Multicenter interventional double-blinded randomized controlled trial,COVID-19 (SARS-CoV-2 infection) vaccine Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,,Government,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Biological/Vaccine,AV-COVID-19,Phase I,Healthy volunteer,Adult,Both,27,
760,ISRCTN82411169,A phase I/II study to evaluate the safety of and immunological response to a vaccine candidate (VLA2001) against COVID-19,"VLA2001-201, IRAS 289098","Approved 23/11/2020, London-Brent Research Ethics Committee (Health Research Authority, Skipton House, 80 London Road, London, SE1 6LH, UK; +44 (0)20 7972 2545; hra.approval@nhs.net), ref: 20/HRA/5205",United Kingdom,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date.,To be made available at a later date,,,Department of Health and Social Care,Valneva (Austria),grid.420366.5,http://dx.doi.org/10.13039/501100000276,31/08/2022,10/07/2020,31/08/2021,16/12/2020,17/01/2021,25/03/2021,17/12/2020,Ongoing,No longer recruiting,Retrospectively registered,2020-005062-33,NCT04671017,A multicenter 3-arm randomized dose finding study,COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,government organisation,Industry,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Biological/Vaccine,VLA2001,Phase I/II,Healthy volunteer,Adult,Both,150,
768,ISRCTN69564614,Moving on trial: COVID-19 and homelessness,CPMS 47728,"Approved 12/08/2020, The School of Geography and Planning Research Ethics Committee (Cardiff University, Glamorgan Building, King Edward VII Avenue, Cardiff, CF10 3WT, UK; +44 (0)2920874022; lumbe@cardiff.ac.uk), ref: 2020_24",United Kingdom,,Findings disseminated through a new MHCLG/CHI Research Network. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date,To be made available at a later date,,,UK Research and Innovation,Cardiff University,grid.5600.3,http://dx.doi.org/10.13039/100014013,01/02/2023,01/08/2020,06/01/2022,06/01/2021,31/03/2021,17/02/2021,16/12/2020,Ongoing,No longer recruiting,Prospectively registered,Nil known,Nil known,Interventional randomized controlled trial,COVID-19 and homelessness Not Applicable,Not Applicable,,private sector organisation,University/education,Randomised controlled trialRandomised controlled trial,Community,Other,Other,,,Other,Adult,Both,1200,
805,ISRCTN27106947,A study to assess several different treatments that may be useful for patients with COVID-19,"UoL001542, CPMS 45759, IRAS 282781","Approved 12/05/2020, West Midlands – Edgbaston Research Ethics Committee (3rd Floor Barlow House, Minshull Street, Manchester, M1 3DZ; +44 (0)20 7104 8122; Edgbaston.rec@hra.nhs.uk), ref: 20/WM/0136",South Africa; United Kingdom,,"Data for each candidate will be analysed and published as soon as possible to ensure the rapid availability of results to avoid duplication from others across the world. To ensure this, in the first instance these results may be published in a non-standard format presenting headline results as soon as possible on Southampton Clinical Trials Unit website (for example) followed by a formal publication. IPD sharing statement Individual participant data will be made available from each AGILE Candidate Specific Trial (CST) Protocol, including data dictionaries, for approved data sharing requests. Individual participant data will be shared that underlie the results reported in any publications, after de-identification and normalisation of information (text, tables, figures, and appendices). The study protocol and statistical analysis plan will also be available. Anonymous data will be available for request from three months after publication of the article, to researchers who provide a completed Data Sharing request form that describes a methodologically sound proposal, for the purpose of the approved proposal and if appropriate, signed a Data Sharing Agreement. Data will be shared once all parties have signed relevant data sharing documentation, covering SCTU conditions for sharing and if required, an additional Data Sharing Agreement from Sponsor. Proposals should be directed to ctu@soton.ac.uk. In addition when the database from each Candidate Specific Trial Protocol is locked, analysed and published we will make the data available to the academic community via www.clinicalstudydatarequest.com",Available on request,,2020 protocol in https://doi.org/10.1186/s13063-020-04473-1 (added 03/12/2020),NIHR Southampton Clinical Trials Unit; Ridgeback Biotherapeutics; National Institute for Health Research,University of Liverpool,TESTING,http://dx.doi.org/10.13039/501100000272,30/11/2022,31/03/2020,30/11/2021,08/09/2020,30/08/2021,04/05/2021,07/12/2020,Ongoing,Recruiting,Retrospectively registered,2020-001860-27,NCT04746183,Multicentre multi-arm multi-dose multi-stage open-label adaptive seamless phase I/II Bayesian randomized platform trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,government organisation,University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,"EIDD-2801 (molnupiravir), nitazoxanide, VIR-7832, VIR-7831",Phase I/II,Patient,Adult,Both,180,
820,ISRCTN11713182,Testing the effectiveness of almitrine bismesylate in the treatment of COVID-19,"CPMS 47241, IRAS 282381","Approved 23/11/2020, North West – Liverpool Central REC, 3rd Floor, Barlow House, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)207 104 8197, +44 (0)2071048387; liverpoolcentral.rec@hra.nhs.uk), REC ref: 20/NW/0415",United Kingdom,,Planned publication in a high-impact peer-reviewed journal IPD sharing statement The data sharing plans for the current study are unknown and will be made available at a later date,To be made available at a later date,,,LifeArc,University of Oxford,grid.4991.5,http://dx.doi.org/10.13039/100012357,30/09/2022,30/04/2020,30/09/2021,21/12/2020,31/03/2021,02/12/2020,02/12/2020,Ongoing,No longer recruiting,Prospectively registered,2020-002567-57,Nil known,"Randomized; Interventional; Design type: Treatment, Drug",COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,private sector organisation,University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,Almitrine bismesylate,Not Applicable,Patient,Adult,Both,116,
822,ISRCTN19845486,"VR Baby, a virtual reality learning environment - does it help medical students to learn about complex topics in obstetrics and gynaecology?",Nil known,"Approved 26/5/2020, Human Research Ethics Committee at University College Dublin (Office of Research Ethics, Roebuck Castle, Belfield, Dublin 4, Ireland; +353 (0)1 716 8767; hrec@ucd.ie), ref: LS-20-09-McAuliffe",Ireland,,1. There is no study protocol available 2. Planned publication in a high-impact peer-reviewed journal IPD sharing statement The datasets generated during and/or analysed during the current study are/will be available upon request from Prof. Fionnuala McAuliffe (fionnuala.mcauliffe@ucd.ie).,Available on request,,,Investigator initiated and funded,University College Dublin,Missing GRID,,01/07/2021,27/01/2020,31/03/2021,01/07/2020,31/10/2020,01/12/2020,02/12/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Single-centre randomized control trial,Effect of virtual reality in medical education (obstetrics and gynaecology) Pregnancy and Childbirth,Pregnancy and Childbirth,,,University/education,Randomised controlled trialRandomised controlled trial,Other,Other,Other,,,Healthy volunteer,Adult,Both,40,56.0
823,ISRCTN77689525,"Sharing Stories: A digital intervention for caregivers with young children in the COVID-19 era to promote child social, emotional and language development, responsive parenting and parental mental wellbeing in Zambia, Tanzania, and Uganda",Nil known,"1. Approved 01/07/2020, Stellenbosch University Health Research Ethics Committee (Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa; +27 (0)21 938 9657; elr@sun.ac.za), ref: N20/06/026_COVID-19 2. Approved 16/07/2020, ERES Converge IRB (33 Joseph Mwilwa Road, Rhodes Park, Lusaka, Zambia; +260 955 155 633; eresconverge@yahoo.co.uk), ref: No.2020-Jul-001 3. Approved 10/09/2020, National Institute for Medical Research (P.O. Box 9653, Dar es Salaam, 11101, Tanzania; +255 22 2121400; nimrethics@gmail.com), ref: NIMR/HQ/R.8a/Vol.IX/3507 4. Approved 27/08/2020, Mbarara University of Science and Technology, (P.O. Box 1410, Mbarara Uganda; +256 485433795; sec.rec@must.ac.ug), ref: MUREC 1/7",Tanzania; Uganda; Zambia,,We intend to publish at least 4 peer reviewed publications from the trial. We will also publish a policy brief. Findings will be presented at local and international conferences. IPD sharing statement: All data generated or analysed during this study will be included in the subsequent results publication.,Other,,,The LEGO Foundation,Stellenbosch University,grid.11956.3a,,01/05/2022,01/06/2020,31/05/2021,25/08/2020,30/11/2020,02/06/2021,02/12/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Pilot interventional randomised controlled trial,"Child social, emotional and language development, responsive parenting, parental mental wellbeing Not Applicable",Not Applicable,,,University/education,Randomised controlled trialRandomised controlled trial,Internet,Prevention,Behavioural,,,Mixed,Mixed,Both,720,734.0
851,ISRCTN11466448,A randomized trial to assess the effects of physical and mental health rehabilitation for people recovering from COVID-19,"CPMS 46819, IRAS 288362","Approved 06/11/2020, East of England – Cambridge South REC (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)2071048065; cambridgesouth.rec@hra.nhs.uk), REC ref: 20/EE/0235",United Kingdom,,"The study protocol will be published in a peer-reviewed journal. The researchers will publish papers in open-access journals describing the development and refinement of the REGAIN intervention, and the study protocol, as per recommended guidance for transparent reporting, the Consolidated Standards of Reporting Trials (CONSORT) guidelines (https://www.consort-statement.org), the NIHR standard terms, and Warwick SOP 22: Publication & Dissemination. The Warwick Clinical Trials Unit will publish the results of the trial on their website when these are available. Publication of the initial trial results, including the primary outcome, will take place as soon as possible (scheduled for January 2022). IPD sharing statement The data sharing plans for the current study are unknown and will be made available at a later date.",To be made available at a later date,,2020 protocol in https://doi.org/10.1186/s13063-020-04978-9 (added 07/01/2021),"NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR132046",University Hospitals Coventry and Warwickshire NHS Trust,grid.15628.38,,01/01/2022,01/09/2020,31/08/2022,30/11/2020,31/12/2021,10/06/2021,23/11/2020,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,"Randomized; Interventional; Design type: Treatment, Education or Self-Management, Psychological & Behavioural, Complex Intervention, Physical, Rehabilitation",COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Other,,,Patient,Adult,Both,535,
853,ISRCTN77941736,Coping during COVID-19: Peer-delivered training to improve adolescent wellbeing,Nil known,"Approved 10/11/2020, University of Oxford, Medical Sciences Interdivisional Research Ethics Committee (Research Services, University of Oxford, Wellington Square, Oxford, OX1 2JD, UK; +44 (0)1865 616577; ethics@medsci.ox.ac.uk), ref: R69810/RE001",United Kingdom,,The full study protocol is not yet available but will be uploaded prior to study completion. Planned publication of the study results in a high-impact peer-reviewed journal. IPD sharing statement: The data-sharing plans for the current study are unknown and will be made available at a later date.,To be made available at a later date,,,Westminster Foundation,University of Oxford,grid.4991.5,,31/05/2021,01/10/2020,30/03/2021,14/11/2020,03/12/2020,04/12/2020,23/11/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Randomized controlled trial,Adolescent mental wellbeing during COVID-19 Mental and Behavioural Disorders Mental wellbeing,Mental and Behavioural Disorders,,,University/education,Randomised controlled trialRandomised controlled trial,Internet,Quality of life,Behavioural,,,Healthy volunteer,Child,Both,120,94.0
857,ISRCTN11970082,Effect of the drug indomethacin in the treatment of COVID-19 patients,CR/20-21/ED/208/ALUM/002553​,"1. Approved 03/08/2020, Institutional Ethics Committee, Narayana Medical College (Nellore 524003, India; +91 (0)8008086119; dean@narayanamedicalcollege.com), ref: NMC/Ethics/Project/006/2020 2. Approved 10/10/2020, Institutional Ethics Committee, Datta Meghe Institute of Medical Sciences (Sawangi (Meghe), Wardha - 442004, Maharashtra, India; +91 (0)7152 287701; icc.dmims@gmail.com), ref: DMIMS(DU)/IEC/2020-21/9034",India,,"Planned publication in a high-impact journal IPD sharing statement The blood tests and CT scans are the data that will be stored and will be available on request from the Principal Investigator of the sites. The request can be sent to the respective centre's ethics committee, who will consider sharing the raw data based on legal and ethical considerations. Consent will be obtained from the participant and data will be anonymised to safeguard the privacy of the participants.",Available on request,,2020 non-peer-reviewed results in preprint https://doi.org/10.1101/2020.12.14.20245266 (added 17/03/2021),"Mr Kris Gopalakrishnan, Alumnus IIT Madras through the Indian Institute of Technology Madras",Indian Institute of Technology Madras,grid.417969.4,,01/02/2021,27/07/2020,01/01/2021,16/08/2020,10/12/2020,17/03/2021,20/11/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Multicenter interventional single-arm open-labelled trial and an academic retrospective study to act as control for comparison,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,Government,Non randomised studyNon randomised study,Hospitals,Treatment,Drug,"Indomethacin, proton pump inhibitor",Not Applicable,Patient,Adult,Both,250,
866,ISRCTN12792822,Cash transfers to stimulate school re-enrollment among vulnerable adolescent girls in urban informal settlements as Kenya responds to COVID-19,p661,"Approved 28/10/2020, Population Council IRB (1230 York Avenue, New York, NY 10065, USA; +1 212 3277112; ngontarz@popcouncil.org), ref: p661",Kenya,,"-Planned publication in a high-impact peer-reviewed journal. -Policy brief that summarizes the lessons learned for non-research audiences IPD sharing statement: The datasets generated during and/or analysed during the current study will be stored in a publically available repository. The de-identified data will be stored in the Adolescent Data Hub. http://popcouncil.org/girlcenter/adolescentdatahub/ The data set from the follow up survey six weeks after the transfer will be made available at the time of the publication of the main results manuscript. The underlying data from the AGI-K cohort is already posted in that repository. The data will be available indefinitely. The person interested in the data will need to submit a request and so long as what they are proposing to do with the data isn’t overlapping with the study investigators ongoing research objectives, the data will be made available for downloading from the site. The consent forms for the study include language on de-identified data from the study being made available open access.",Stored in repository,,,Echidna Giving; Bill and Melinda Gates Foundation; UK Aid - Kenya,Population Council - Kenya,Missing GRID,http://dx.doi.org/10.13039/100000865,30/06/2022,02/10/2020,30/06/2021,21/11/2020,15/12/2020,16/03/2021,18/11/2020,Completed,No longer recruiting,Prospectively registered,Nil known,Nil known,Individual randomized controlled trial,Increasing school enrollment among adolescent girls after the long-term COVID-19 school closures Not Applicable,Not Applicable,,private sector organisation,Research organisation,Randomised controlled trialRandomised controlled trial,Home,Prevention,Behavioural,,,Healthy volunteer,Child,Female,1700,
870,ISRCTN90437126,Study on the effects of using ivermectin to prevent COVID-19 in an adult population in Brazil,IvermecPrev-Brazil ScinetN001.2020,"Approved 06/06/2020, National Commission for Research Ethics (CONEP) (Ministério da Saúde - Esplanada dos Ministérios Edifício Anexo Bl. G Ala B Sl. 13-B, 70.058-900, Brasíl; +55 61 3315-295; conep@saude.gov.br), ref: 31523220.0.1001.0008",Brazil,,"Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. What data in particular will be shared? Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). What other documents will be available? Study Protocol When will data be available (start and end dates)? Beginning 3 months and ending 36 months following article publication. With whom? Researchers who provide a methodologically sound proposal. For what types of analyses? To achieve aims in the approved proposal. For individual participant data meta-analysis By what mechanism will data be made available? Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at (Link to be provided).",Available on request,,,Clinical Research Institute Scinet; Mamanguape’s Health Secretariat,Federal University of Pernambuco; Clinical Research Institute Scinet,grid.411227.3,,15/08/2022,10/04/2020,30/06/2022,15/09/2020,30/11/2021,31/03/2021,17/11/2020,Ongoing,Recruiting,Retrospectively registered,Nil known,Nil known,Two-armed randomized controlled trial,Prevention of COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,Research organisation,Randomised controlled trialRandomised controlled trial,GP practices,Prevention,Drug,Ivermectin,Phase III,Healthy volunteer,Adult,Both,800,
898,ISRCTN16842454,Effectiveness and safety of plasma convalescent therapy in patients with COVID-19,003,"Approved 09/05/2020, Ministry of Health-National Institute of Health Research and Development (Jl Percetakan Negara No. 29 Jakarta 10560, Postcode: 1226; +62 (0)214261088; scsban@litbang.depkes.go.id), ref: LB.02.01/KE 351/2020",Indonesia,,Planned publication in a high-impact peer-reviewed journal IPD sharing statement Data will be available upon request from Ika Kartiyani (ikakartiyani@gmail.com).,Available on request,,,KEMENRISTEK/BRIN Indonesia,Ministry of Research and Technology/National Research and Innovation Agency (Kementerian Riset dan Teknologi Republik Indonesia),Missing GRID,,20/12/2020,26/04/2020,13/12/2020,19/05/2020,12/12/2020,10/11/2020,10/11/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Non-randomized trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,Government,Non randomised studyNon randomised study,Hospitals,Treatment,Biological/Vaccine,Convalescent plasma,Not Applicable,Patient,Adult,Both,5,
903,ISRCTN25647404,Measurement of the effect of mouthwash against COVID-19 ,IRAS 285247,"Approved 27/7/20, South Central - Berkshire B Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 1048310; berkshireb.rec@hra.nhs.uk), REC ref: 20/SC/0275",United Kingdom,,"Planned publication in a high impact journal. The impact of this work may be significant in managing patients and there is a genuine desire to see and employ the results of the study (if positive) in the NHS and Welsh Assembly Government. Once the data is analysed, if positive, the results will initially be disseminated via the Chief Dental and Chief Medical Officers and submitted for publication with minimum delay. IPD sharing statement Data will be available on request via communication with the PI Prof. David Thomas (thomasdw2@cardiff.ac.uk). The data will include the patient number in the study, mouthwash given and viral load in saliva at baseline and at each timepoint after administration of the mouthwash. No other data is recorded and the data is anonymised. The patients have given consent for the data to be stored.",Available on request,,,Venture Life,Cardiff University,grid.5600.3,,01/02/2021,20/05/2020,27/12/2020,20/09/2020,27/12/2020,09/11/2020,09/11/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Four-arm randomized controlled trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Other,,,Patient,Adult,Both,104,
906,ISRCTN10989132,ASK: Improving access to kidney transplantation,"IRAS 287507, Sponsor's number 2020-4883, WT 214554/Z/18/Z","Approved 12/01/2021, West Midlands - South Birmingham Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 104 8388; southbirmingham.rec@hra.nhs.uk), ref: 21/WM/0003",United Kingdom,,"The results of the study will be published in peer-reviewed journals and all participants will be offered a plain English summary of the main findings of the study. IPD sharing statement: The datasets generated during and/or analysed during the current study will be stored in a publically available repository. At recruitment participants will be asked to provide written consent for sharing of anonymised data with other researchers. Data from participants who consent to this will be made available to other researchers on request after a period of exclusive use by the researchers of five years following completion of the study. The study team will have exclusive use of the data to design and secure funding for a full-scale RCT. Data will be uploaded to the University of Bristol’s Research Data Repository: https://data.bris.ac.uk/data/ A summary of the data available will be detailed on the study website and all publications arising from the research. Potential new users can also actively search the University of Bristol’s data repository. Audio files of the recorded interviews will not be suitable for sharing as they carry a high risk of allowing the research participant to be identified, and the content of interviews will potentially be highly sensitive. Although the qualitative transcripts will be anonymised as personal issues will be discussed we cannot rule out the risk of identification. Therefore access to these transcripts will be controlled. Requests for Controlled data through UoB are referred to an appropriate Data Access Committee (DAC) for approval, before data can be shared with researchers, after their host institution has signed a Data Access Agreement. The DAC comprises: Assistant Director of Research Services, Information Rights Officer, Head of Research Governance, Assistant Director IT Services, Research Contracts, Academics - the PI. The procedure for accessing data can be found here: https://www.bristol.ac.uk/staff/researchers/data/accessing-research-data/",Stored in repository,,,Wellcome Trust; Kidney Care UK,University of Bristol,grid.5337.2,http://dx.doi.org/10.13039/100010269,01/02/2024,01/01/2018,01/02/2023,01/07/2021,01/08/2022,11/05/2021,06/11/2020,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,Two-arm parallel group pragmatic individually-randomised controlled feasibility trial of a complex multicomponent intervention,Improving access to living-donor kidney transplantation for people with advanced kidney disease Urological and Genital Diseases Renal disease,Urological and Genital Diseases,,private sector organisation,University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Other,Other,,,Patient,Adult,Both,60,
912,ISRCTN14722499,A study of the Ad26.COV2.S vaccine candidate for the prevention of SARS-CoV-2-mediated COVID-19 in adults,"Protocol-ID VAC31518COV3009, IRAS 288552, CPMS 46804","Approved 09/11/2020, Yorkshire & The Humber - Sheffield Research Ethics Committee (NHS Blood and Transplant Blood Donor Centre, Holland Drive, Newcastle upon Tyne, Tyne and Wear, NE2 4NQ, UK; +44 (0)207 104 8029; sheffield.rec@hra.nhs.uk), REC ref: 20/YH/0317",Belgium; Colombia; France; Germany; Philippines; South Africa; Spain; United Kingdom; United States of America,,"1. The study protocol (redacted version) will be made available on ClinicalTrials.gov at the time of results submission to ClinicalTrials.gov 2. Planned publication of the study results in a peer-reviewed journal IPD sharing statement The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at yoda.yale.edu.",Available on request,,,Janssen Pharmaceuticals,Janssen (Netherlands),grid.497529.4,http://dx.doi.org/10.13039/100008897,10/05/2024,15/07/2020,10/05/2023,15/11/2020,12/03/2021,20/04/2021,04/11/2020,Ongoing,No longer recruiting,Prospectively registered,2020-003643-29,NCT04614948,Multi-centre randomized double-blind placebo-controlled parallel-group study with staggered enrollment strategy,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,private sector organisation,Industry,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Biological/Vaccine,"Ad26.COV2.S, JNJ-78436735, VAC31518",Phase III,Mixed,Mixed,Both,30000,
914,ISRCTN79623250,The digital Hope programme for people living with cancer during COVID-19,IRRID: RR1-10.2196/24264,"Approved 28/04/2020, Coventry University Ethics Committee (Coventry University, Priory Street, Coventry, West Midlands, CV1 5FB, UK; no telephone number provided; ethics.uni@coventry.ac.uk), ref: P106024",United Kingdom,,"Planned publication of feasibility RCT results in Journal of Medical Internet Research. Raw data will be available to the research team only, as per study ethical approval. IPD sharing statement: The datasets generated during and/or analysed during the current study are not expected to be made available due to ethical conditions.",Not expected to be available,,2020 protocol in https://pubmed.ncbi.nlm.nih.gov/33237877/ (added 12/01/2021),Investigator initiated and funded,Coventry University,grid.8096.7,,31/07/2021,31/03/2020,02/09/2020,30/04/2020,03/05/2020,10/05/2021,04/11/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Feasibility 1:1 randomized waitlist controlled trial,Self-management for people with cancer Cancer,Cancer,,,University/education,Randomised controlled trialRandomised controlled trial,Internet,Other,Behavioural,,,Patient,Adult,Both,40,41.0
918,ISRCTN15874265,Study to assess the safety and effectiveness of remdesivir in people with severe COVID-19,"GS-US-540-5773, IRAS 282007, CPMS 45460","Approved 25/03/2020, North East - Tyne & Wear South Research Ethics Committee (HRA Jarrow, Room 001, Jarrow Business Centre, Rolling Mill Road, Jarrow, NE32 3DT, UK; +44 (0)207 1048084; nrescommittee.northeast-tyneandwearsouth@nhs.net), ref: 20/NE/0104","France; Germany; Hong Kong; Italy; Japan; Korea, South; Netherlands; Singapore; Spain; Sweden; Switzerland; Taiwan; United Kingdom; United States of America",,"Planned publication in a high-impact peer-reviewed journal. The Protocol is available at the following address within the supplemental materials: https://www.nejm.org/doi/full/10.1056/NEJMoa2015301 A redacted version of the latest protocol and statistical analysis plan, will be available on ClinicalTrials.gov when results are submitted: https://clinicaltrials.gov/ct2/show/NCT04292899 IPD sharing statement: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Gilead Sciences shares anonymized individual patient data upon request or as required by law or regulation with qualified external researchers based on submitted curriculum vitae and reflecting non conflict of interest. The request proposal must also include a statistician. Approval of such requests is at Gilead Science’s discretion and is dependent on the nature of the request, the merit of the research proposed, the availability of the data, and the intended use of the data. Data requests should be sent to datarequest@gilead.com . Data will become available 18 months after study completion and will be accessible in a secured external environment. More information on Gilead’s data sharing policy can be found here: https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy",Available on request,"https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/results, https://clinicaltrials.gov/ct2/show/results/NCT04292899",2020 results in https:doi.org/10.1056/NEJMoa2015301 (added 29/10/2020),Gilead Sciences,Gilead Sciences (United States),grid.418227.a,http://dx.doi.org/10.13039/100005564,01/06/2021,11/02/2020,30/06/2020,06/03/2020,29/05/2020,19/03/2021,03/11/2020,Completed,No longer recruiting,Retrospectively registered,2020-000841-15,NCT04292899,Phase 3 randomized open-label multi-center study,COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,government organisation,Industry,Randomised parallel trialRandomised parallel trial,Hospitals,Treatment,Drug,Remdesivir (RDV),Phase III,Patient,Other,Both,6000,4891.0
959,ISRCTN12890382,Child anxiety treatment in the context of COVID-19,"IRAS 288074, CPMS 46902","Approved 04/09/2020, London - City & East Research Ethics Committee (Bristol Research Ethics Committee Centre, Whitefriars, Level 3 Block B, Lewins Mead, Bristol, BS1 2NT, UK; +44 (0)207 104 8214; cityandeast.rec@hra.nhs.uk), ref: 20/HRA/4431",United Kingdom,,"Planned publication in a high -impact peer-reviewed journal. A summary of the study findings will be circulated at the end of the study to all participating clinical teams and families. Anonymised trial data will be made available open access on completion of the trial, details of this to be added later. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date.",To be made available at a later date,,,UK Research and Innovation (UKRI) COVID-19 Rapid Response Initiative,University of Oxford,grid.4991.5,,31/08/2022,01/09/2020,30/05/2022,02/11/2020,31/10/2021,29/04/2021,23/10/2020,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,Interventional multi-site two-arm parallel-group randomized controlled non-inferiority trial,Anxiety problems in children aged 5-12 Mental and Behavioural Disorders,Mental and Behavioural Disorders,,,University/education,Randomised controlled trialRandomised controlled trial,Other,Treatment,Behavioural,,,Patient,Child,Both,560,
1008,ISRCTN18428598,Does the Flexible Phonics programme lead to improved reading outcomes for children in Reception when taught in addition to existing phonics programmes/practice?,Nil known,"Approved 13/01/2020, Research Ethics Panel of the Institute for Employment Studies (IES) (City Gate, 185 Dyke Road, Brighton, BN3 1TL; +44 (0) 1273 763 400; becci.newton@employment-studies.co.uk), ref: not applicable",United Kingdom,,"The protocol for the trial is available at https://educationendowmentfoundation.org.uk/projects-and-evaluation/projects/flexible-phonics/ A statistical analysis plan will also be published on the same site in 2021. The final report presenting the trial results will be made available in a publicly available report on the website of the Education Endowment Foundation; we anticipate this will be published in Summer 2022, an addendum report including further analysis of long-term effects using the Phonics screening at the end of Year 1 will be published in Spring 2023. IPD sharing statement The datasets generated during and/or analysed in this study will be stored in a non-publicly available repository; the Education Endowment Foundation (EEF) Data Archive, which is managed by the Fischer Family Trust (FFT). Further details are available here: https://educationendowmentfoundation.org.uk/public/files/Evaluation/Submitting_your_data_to_the_FFT_archive/Archiving_EEF_project_data.pdf. These data will be submitted to the archive by the evaluation team within 3 months of project completion. The dataset will be at an individual level (i.e. one row per pupil), including information on the treatment they receive and the outcomes of testing (at baseline and follow-up). The data will be archived for an indefinite period for archiving, historical or scientific research purposes, with access criteria determined by the EEF and FFT. The legal basis for processing data is legitimate interests, with individuals able to express objections to data processing. Data will be available in a pseudo-anonymised format so that future analysis incorporating data from the National Pupil Database (NPD) could be facilitated.",Stored in repository,,,Education Endowment Foundation,Education Endowment Foundation,grid.484108.1,http://dx.doi.org/10.13039/100012343,01/06/2022,01/06/2019,31/01/2023,01/01/2020,12/10/2020,01/10/2020,08/10/2020,Ongoing,No longer recruiting,Retrospectively registered,Nil known,Nil known,Two-arm multi-centre cluster randomized controlled efficacy trial with pupil-level outcomes,"Early years literacy, with a focus on exception words Not Applicable",Not Applicable,,private sector organisation,Charity,Cluster randomised trialCluster randomised trial,Schools,Other,Behavioural,,,Other,Child,Both,2875,
1019,ISRCTN10197987,The possible beneficial role of the regular use of potent mouthwash solutions in the treatment of COVID-19,MRC 05-106,"Approved 20/08/2020, Hamad Medical Corporations' Medical Research Center IRB (Medical Research Center, Hamad Medical City, Doha, Qatar; +974 (0)5554 6316; IRB@hamad.qa), ref: MRC 05-106",Qatar,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement The data sharing plans for the current study are unknown and will be made available at a later date.,To be made available at a later date,See additional files,2020 non-peer-reviewed results in preprint https://doi.org/10.1101/2020.11.27.20234997 (added 16/03/2021),Hamad Medical Corporation,Hamad Medical Corporation,grid.413548.f,,30/11/2020,30/04/2020,20/11/2020,08/09/2020,01/10/2020,05/05/2021,05/10/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Interventional randomized parallel trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,Industry,Randomised parallel trialRandomised parallel trial,Hospitals,Treatment,Other,,,Patient,Adult,Both,100,100.0
1052,ISRCTN57085639,A platform to investigate the safety and effectiveness of several new medicines for the treatment of COVID-19 in hospitalised patients,"CPMS 45616, IRAS 282769","Approved 24/04/2020 South Central – Oxford C Research Ethics Committee (Level 3, Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT, UK; +44 (0)207 972 2496; oxfordc.rec@hra.nhs.uk), ref: 20/SC/0201",United Kingdom,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: All data generated or analysed during this study will be included in the subsequent results publication,Other,,2020 protocol in https://pubmed.ncbi.nlm.nih.gov/32736596/ (added 25/03/2021),BerGenBio AS,University Hospital Southampton NHS Foundation Trust,grid.430506.4,,04/09/2022,20/04/2020,04/09/2021,08/05/2020,08/05/2021,09/04/2021,24/09/2020,Ongoing,No longer recruiting,Retrospectively registered,2020-001736-95,Nil known,Interventional randomized controlled trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,"Bemcentinib, MEDI-3506, acalabrutinib, zilucoplan",Phase II,Patient,Adult,Both,1800,
1054,ISRCTN53038326,IMU838 and oseltamivir in the treatment of COVID-19,"CPMS 45777, IRAS 282532","Approved 15/05/2020, Wales Research Ethics Committee 1 Cardiff (Health and Care Research Wales, Castlebridge 4 15-19, Cowbridge Road East, Cardiff, CF11 9AB, UK; +44 (0)2920 785738; Wales.REC1@wales.nhs.uk), REC ref: 20/WA/0146",United Kingdom,,"1. Planned publication of the protocol 2. All efforts will be made to ensure that the results arising from the study are published in a timely fashion, in established peer-reviewed journals. Results will be disseminated to collaborators, colleagues, health professionals and participants via internal and external conferences and seminars, newsletters, and via interested groups, including local healthcare commissioning groups. The researchers are working on a formalised publication plan targeting specific journals and will update accordingly. IPD sharing statement Data from this study will be made available to researchers who provide a methodologically sound proposal in writing to the Sponsor, following the publication of the main study paper. Anonymised, individual participant data, data dictionary, study protocol and statistical analysis plan will be accessible upon application.",Available on request,,,Immunic AG; LifeArc,University Hospitals Coventry and Warwickshire NHS Trust,grid.15628.38,http://dx.doi.org/10.13039/100012357,15/05/2022,23/03/2020,15/11/2021,22/06/2020,30/09/2021,21/05/2021,23/09/2020,Ongoing,Recruiting,Retrospectively registered,2020-001805-21,NCT04516915,"Randomized; Interventional; Design type: Treatment, Drug",COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,private sector organisation,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,"IMU838, oseltamivir",Phase II,Patient,Adult,Both,120,
1082,ISRCTN51232965,"An interventional study to evaluate the safety and immune response of a vaccine against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2, the virus that causes COVID-19 infection) when given to healthy adult participants",UQ-1-SARS-CoV-2-Sclamp,"Approved 07/07/2020, Alfred Hospital Ethics Committee (55 Commercial Road, Melbourne VIC 3004, Australia; +61 (0)390768825; research@alfred.org.au), ref: 334/20",Australia,,"Planned publication in a high-impact peer-reviewed journal. The researchers will be preparing a separate protocol publication. IPD sharing statement Individual participant data underlying published results only on a case-by-case basis at the discretion of the Primary Sponsor. Christina Henderson, UQ Project Manager (rapid.response.trials@uq.edu.au) will be the contact for access to the datasets. Individual participant data that underlie the results reported in the [published] article, after de-identification (text, tables, figures, and appendices) will be available, immediately after publication with no end date. The data will be shared with researchers who provide a methodologically sound proposal and who reach out to the nominated contact, for analyses required to achieve the aims in the approved research proposal. Proposals should be directed to rapid.response.trials@uq.edu.au. To gain access, data requestors will need to sign a data access agreement.",Available on request,,,University of Queensland; Coalition for Epidemic Preparedness Innovations,University of Queensland,grid.1003.2,http://dx.doi.org/10.13039/501100001794; http://dx.doi.org/10.13039/100016302,25/09/2022,16/03/2020,22/09/2021,13/07/2020,25/08/2020,10/09/2020,14/09/2020,Ongoing,No longer recruiting,Retrospectively registered,Nil known,NCT04495933,Single-centre interventional double-blinded placebo-controlled randomized trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,unknown,University/education,Randomised controlled trialRandomised controlled trial,Other,Prevention,Biological/Vaccine,MF59 adjuvanted SARS-CoV-2 Sclamp vaccine,Phase I,Healthy volunteer,Adult,Both,216,216.0
1083,ISRCTN34160010,A low-intervention study of pre-exposure prophylaxis (PrEP) in healthy volunteers at high risk of coronavirus (SARS-CoV-2) infection.,MIBVD-19,"Approved 27/05/2020, Local Ethics Committee at North-Western State Medical University named after I.I. Mechnikov (NWSMU) (41 Kirochnaya street, Russian Federation, 191015; +7 8123035000; rectorat@szgmu.ru), ref: 4.",Russian Federation,,Study protocol with statistical analysis plan (SAP) and informed consent form (ICF) will be included as supplementary materials in the subsequent results publication in a peer-reviewed journal. IPD sharing status: Informed consent will be obtained from all participants of the study. Request for individual de-indentified participant data must be sent to Prof. Michael Dubina at michael.dubina@gmail.com. The data will be available with the subsequent result publication. The data will be made available to researchers whose proposed use of the data has been approved (for a specified purpose).,Available on request,,2021 results in https://pubmed.ncbi.nlm.nih.gov/34098889/ (added 09/06/2021),North-Western State Medical University named after I.I. Mechnikov,North-Western State Medical University named after I.I. Mechnikov,grid.445925.b,,30/10/2020,22/04/2020,02/09/2020,01/06/2020,10/07/2020,09/06/2021,14/09/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Low-intervention prospective open-label single-centre investigator-initiated study,"COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection), coronavirus Infection, coronavirus",Infections and Infestations,,,University/education,Non randomised studyNon randomised study,Hospitals,Prevention,Drug,"Inosine-glutamyl-cysteinyl-glycine disodium, potassium chloride",Not Applicable,Health professional,Adult,Both,100,99.0
1101,ISRCTN13177364,"The development, testing and evaluation of a COVID-19 fundamental nursing care protocol","MR/V02776X/1, IRAS 287288, CPMS 46874","Approved 31/07/2020, University of Exeter Medical School (Knowledge Spa, Royal Cornwall Hospital, Truro, Cornwall, TR1 3HD, UK; +44 (0)1872 256460; c.barkle@exeter.ac.uk), ref: 20/07/256",United Kingdom,,"1. The study protocol is being submitted for publication. 2. Publication planned in high-quality peer-reviewed academic journals and professional journals. 3. Guidelines, education materials and strategies accessible via Health Education England, the Open University’s FutureLearn web platform, and through experienced NHS sites acting as training and dissemination hubs for other health Trusts, environments such as care homes, and global health systems. IPD sharing statement Participants will be identified by a unique study ID. Personal identifiable data including date of birth and NHS number may be collected but will be stored separately to research data and will be destroyed as per applicable regulations when the project is concluded. Data will be managed by the UKCRC registered Exeter Clinical Trials Unit (ExeCTU) following GDPR and data protection guidelines and all relevant Clinical Trial Regulations. All data will be anonymised prior to publication. Data will be collected and stored electronically in accordance with the Data Protection Act 2018 and ICH GCP E6 R2. ExeCTU will use Redcap Cloud Electronic Data Capture System to collect all case report data. This system is validated to ISO27001 standards, backed up and maintained in Europe. This system is fully compliant to GDPR regulations and managed by ExeCTU. Any additional study data will be stored and backed up on the secure ExeCTU servers, maintained by ExeCTU. Data will be cleaned and validated appropriately and a full Data Protection Impact Assessment (DPIA) will be undertaken along with the development of a comprehensive Data Management Plan (DMP) before the first participant is recruited. Where data are disseminated (e.g. via report, presentation or publication), they will be anonymised. The researchers will align all confidentiality and data handling with the Caldicott Principles. Anonymised data will be stored indefinitely on a research data storage system provided by the University of Exeter called Open access Research Exeter (ORE) for archiving (http://www.exeter.ac.uk/research/openresearch/policies/ore/).",Stored in repository,,2021 protocol in https://pubmed.ncbi.nlm.nih.gov/34039574/ (added 28/05/2021),National Institute for Health Research,University of Exeter,grid.8391.3,http://dx.doi.org/10.13039/501100000272,01/12/2021,20/07/2020,19/10/2021,01/11/2020,08/09/2021,28/05/2021,09/09/2020,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,Cluster randomized controlled trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,government organisation,University/education,Cluster randomised trialCluster randomised trial,Hospitals,Treatment,Behavioural,,,Patient,Adult,Both,840,
1104,ISRCTN95933274,Efficacy of mouth-rinses in reducing SARS CoV-2 viral load in the saliva of COVID-19 positive patients ,329/2020,"Approved 17/06/2020, Centralised Institutional Review Board (168 Jalan Bukit Merah, #06-08 Tower 3 Connection One, Singapore, 150168; +65 (0)6323 7515; irb@singhealth.com.sg), ref: 2020/2537",Singapore,,The protocol will be included in future publications. The results of the study will be published as soon as a reasonable conclusion is made from the study in a high-impact peer-reviewed journal. IPD sharing statement The datasets generated during and/or analysed during the current study are/will be available upon request from A/Prof.C.J. Seneviratne (jaya.seneviratne@ndcs.com.sg).,Available on request,,2020 results in https://pubmed.ncbi.nlm.nih.gov/33315181/ (added 16/12/2020),National Dental Centre of Singapore,National Dental Centre of Singapore,grid.418282.5,,16/06/2022,15/04/2020,16/06/2021,30/06/2020,16/06/2021,16/12/2020,09/09/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Single-centre interventional clinical trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,Research organisation,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Other,,,Patient,Adult,Both,68,36.0
1109,ISRCTN31062548,"GETAFIX (Glasgow Early Treatment Arm Favipiravir) – a study to compare the effectiveness of adding the antiviral drug favipiravir to standard care in COVID-19 patients, compared with standard care alone","CPMS 46289, IRAS 283151","Approved 20/05/2020, West of Scotland Research Ethics Committee 1 (Ward 11, Dykebar Hospital, Grahamston Road, Paisley PA2 7DE; +44 (0)141 314 0212; WoSRec1@ggc.scot.nhs.uk), ref: 20/WS/0073",United Kingdom,,Planned publication in a high-impact peer-reviewed journal. The study protocol will also be submitted for publication. IPD sharing statement: The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication,Other,,2020 protocol in https://pubmed.ncbi.nlm.nih.gov/33213530/ (added 23/11/2020),"Chief Scientist Office, Scottish Government Health and Social Care Directorate; National Institute for Health Research (NIHR) (UK)",NHS Greater Glasgow and Clyde,grid.413301.4,http://dx.doi.org/10.13039/100014589; http://dx.doi.org/10.13039/501100000272,31/12/2021,01/04/2020,31/12/2021,14/09/2020,31/12/2020,19/03/2021,07/09/2020,Ongoing,No longer recruiting,Prospectively registered,2020-001904-41,Nil known,"Single centre, open-label randomized controlled trial",COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,government organisationgovernment organisation,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Other,Treatment,Drug,Favipiravir,Phase II,Patient,Adult,Both,302,
1154,ISRCTN33260034,Adalimumab for coronavirus in community care,IRAS 287434,"Approved 23/09/2020, South Central - Berkshire Research Ethics Committee (Bristol REC Centre, Whitefriars, Level 3, Block B, Lewins Mead, Bristol, BS1 2NT; +44 (0)207 104 8224; berkshire.rec@hra.nhs.uk), ref: 20/SC/0352",United Kingdom,,"Publications will acknowledge the funders with the following text: The research was funded by the Wellcome Trust (221575/Z/20/Z) and Sandoz. The study drug is initially being provided free-of-charge by Sandoz, who had no part in the study design, conduct or analysis. The publication policy will be implemented taking into account the principles of research transparency. The Trial Management Group will be responsible for drafting the main reports from the study and for review of any other reports. In general, papers initiated by the Group (including the primary manuscript) will be written in the name of the AVID-CC protocol, with individual investigators named personally at the end of the report (or, to comply with journal requirements, in web-based material posted with the report). This trial is a response to the public health emergency of COVID-19. Consistent with the statement by Wellcome Trust and other leading research institutions we will: • Seek to publish the clinical findings of the study in a peer reviewed journal as soon as possible after they are available • Make peer-reviewed research publications resulting from this work available through open access • Share the research findings with the WHO upon journal submission • Make research findings available via preprint servers before journal publication • Data generated by this project will be deposited, where possible and appropriate, in sustainable, community databases (e.g. Transmart, Zenodo, FlowRepository) along with appropriate metadata to promote their findability, accessibility, interoperability and reusability. We will actively encourage access to the clinical data. Access will not be unreasonably withheld but we will require that proposers provide a robust analysis and dissemination plan prior to accessing the data. In addition, results will be uploaded to the European Clinical Trial (EudraCT) Database within 6 months of the end of trial declaration by the CI or their delegate. IPD sharing statement: The datasets generated during and/or analysed during the current study will be stored in a publically available repository.",Stored in repository,,,Wellcome Trust,University of Oxford,grid.4991.5,http://dx.doi.org/10.13039/100010269,01/06/2022,01/07/2020,31/12/2021,20/10/2020,30/09/2021,18/01/2021,20/08/2020,Ongoing,Recruiting,Prospectively registered,2020-003628-18,Nil known,Multi-centre interventional open label randomised controlled trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,private sector organisation,University/education,Randomised controlled trialRandomised controlled trial,Community,Treatment,Drug,Adalimumab administered as Hyrimoz,Phase II,Patient,Adult,Both,750,
1184,ISRCTN14602359,COVID-19 Germ Defence: a website to improve infection control during the COVID-19 pandemic,"CPMS 46740, IRAS 287978, UKRI (MRC) MC_PC_19068, UoB 2020-3213","Approved 2/9/2020, Yorkshire & The Humber - Leeds West Research Ethics Committee (NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle upon Tyne, NE2 4NQ, UK; +44 (0)207 104 8018; leedswest.rec@hra.nhs.uk), ref: 20/YH/0261",United Kingdom,,"Findings will be presented at primary care and behaviour change conferences e.g. those of the Society of Academic Primary Care (SAPC), the Royal College of General Practitioners (RCGP) and the UK Society for Behavioural Medicine (UKSBM). Peer-reviewed journal papers will be produced reporting the results and submitted to high impact journals (e.g. British Journal of Public Health, British Journal of General Practice). In order to influence policy and inform healthcare practice, the researchers will collaborate with University of Bristol’s Policy Bristol team and use their links with NHS England, the Royal College of General Practitioners (RCGP) and Public Health England (PHE) to disseminate their findings. The researchers will also consider writing blog posts e.g. for GPOnline, Commissioning Elf and The Conversation. A plain-language summary of the findings will be made available to study participants and members of the public via the Germ Defence website, GP practices and social media. IPD sharing statement Data will not be made available for sharing until after publication of the main results of the study. Thereafter, anonymised data will be made available for secondary research, conditional on assurance from the secondary researcher that the proposed use of the data is compliant with the Medical Research Council (MRC) Policy on Data Preservation and Sharing regarding scientific quality, ethical requirements and value for money. A minimum requirement with respect to scientific quality will be a publicly available pre-specified protocol describing the purpose, methods and analysis of the secondary research, e.g. a protocol for a Cochrane systematic review. Data requests should be made to the Principal Investigator Dr Jeremy Horwood by emailing germdefence-study@bristol.ac.uk.",Available on request,,2021 protocol in https://pubmed.ncbi.nlm.nih.gov/33836825/ (added 12/04/2021),"UK Research and Innovation; National Institute for Health Research, Applied Research Collaboration West (NIHR ARC West); NIHR Health Protection Research Unit (HPRU) in Behavioural Science and Evaluation",University of Bristol,grid.5337.2,http://dx.doi.org/10.13039/100014013,31/12/2021,30/03/2020,10/03/2021,01/10/2020,09/03/2021,20/04/2021,12/08/2020,Completed,No longer recruiting,Prospectively registered,Nil known,Nil known,Single-centre two-arm cluster randomised controlled trial,Respiratory tract infections including COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,private sector organisation,University/education,Cluster randomised trialCluster randomised trial,GP practices,Prevention,Behavioural,,,Patient,Adult,Both,6822,459.0
1189,ISRCTN74727214,Effect of the anti-inflammatory test drug anakinra in patients with coronavirus (COVID-19) requiring oxygen support,Nil known,"Approved 15/06/2020, Medical Research Ethics Committee (College of Medicine and Health Sciences, Sultan Qaboos University, Oman. P.O Box 35. Al Khodh 123; + 968-24141103; mrec@squ.edu.om), ref: SQU-EC/169/2020 MREC #2136",Oman,,Planned publication of the study results in a peer-reviewed journal. IPD sharing statement: The data sharing plans for the current study are unknown and will be made available at a later date.,To be made available at a later date,,2020 results in https://pubmed.ncbi.nlm.nih.gov/33217576/ (added 15/01/2021),OQ,Sultan Qaboos University,grid.412846.d,,31/10/2020,25/05/2020,15/08/2020,15/06/2020,25/07/2020,15/01/2021,10/08/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Single-center interventional study with a retrospectively derived historical control cohort as the comparator group.,Severe COVID-19 (SARS-CoV-2 infection) Respiratory COVID-19 (SARS-CoV-2 infection),Respiratory,,,University/education,Non randomised studyNon randomised study,Hospitals,Treatment,Drug,"Anakinra (brand name Kineret). Swedish Orphan Biovitrum, Stockholm, Sweden.",Not Applicable,Patient,Adult,Both,75,75.0
1202,ISRCTN13455972,Evaluation of coronavirus self-isolation interventions,TP_2020065,"Approved 23/07/2020, Public Health England Research Ethics and Governance Group (REGG) (PHE Research Support and Governance Office, Porton Down, Salisbury, Wilts, SP4 0JG, UK; +44 (0)1980 612922; Elizabeth.Coates@phe.gov.uk), ref: R&D 403",United Kingdom,,"The trial results will initially be reported directly to the Test & Trace Programme within DHSC and PHE and other Government departments, including No. 10 and Cabinet Office. Any further dissemination will be agreed between the investigators, PHE and DHSC following the trial. IPD sharing statement Since the participants of the trial will be close contacts of the confirmed COVID-19 cases, they can be potentially identified if the researchers make the data publicly available. To best protect their data privacy, their data will be stored securely in the DHSC data environment and analysed using DHSC laptops.",Not expected to be available,,,Department of Health and Social Care NHS Test and Trace Programme,Department of Health and Social Care,grid.57981.32,,30/09/2020,01/07/2020,30/09/2020,04/08/2020,05/09/2020,30/10/2020,04/08/2020,Completed,No longer recruiting,Prospectively registered,Nil known,Nil known,Randomised controlled field trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,Government,Randomised controlled trialRandomised controlled trial,Home,Prevention,Behavioural,,,Other,Adult,Both,10000,
1211,ISRCTN93382525,STAR (Study of Trauma And Recovery): a trial of trauma-focused psychological therapy for psychosis,"NIHR 128623, IRAS 275697, CPMS 46008","Approved 24/07/2020, Camberwell St Giles Research Ethics Committee (Health Research Authority, Skipton House, 80 London Road, London, SE1 6LH, UK; +44 (0)207 1048138; camberwellstgiles.rec@hra.nhs.uk), ref: 20/LO/0853",United Kingdom,,"Our main outputs will be academic publications; final study report; conference presentations; clinical workshops; publication of a treatment manual; synopsis of findings, in plain English, to participants and experts-by-experience groups, including our LEAP groups. We will submit the trial protocol, main trial results, cost-effectiveness results, and qualitative interviews findings to the highest-ranking peer-reviewed scientific journal possible (such as JAMA Psychiatry; Lancet Psychiatry; Schizophrenia Bulletin). We will publish in Open Access format to enable experts-by-experience and clinicians to access the findings free of charge. We will convene a symposium to present the findings and the therapy procedures, and provide a 1-day therapy workshop, at the annual meeting of the British Association of Behavioural and Cognitive Psychotherapy, and will present the main trial results at two international conferences (International Congress On Schizophrenia Research, and Annual Meeting of International CBTp group). One of the key outputs of this study will be the publication of the final, detailed treatment manual, which will include specific guidelines for the delivery of therapy and operational guidelines for its application, including case examples. The availability of the manual will enable the therapy to be applied by CBT-trained therapists throughout the NHS. The applicants, and our collaborators, have authored the main manuals of CBTp and related therapies, used internationally, and therefore the team is well placed to ensure successful publication and dissemination of the therapy protocol. Patient and public involvement (PPI) and dissemination: PPI is included at three levels: consultation, collaboration and expert-by-experience led research. We have a long history of PPI in our clinics, research, training, and dissemination of our work. One outcome from this study will be to publish the final therapy manual. The applicants include a clinical-academic with lived experience, who will lead on all PPI aspects of the application, and all the leading UK experts in trauma and psychosis, who have lead roles on NICE committees and provide national training on talking therapies in psychosis. We are therefore well-placed to ensure the successful roll-out of the therapy, should the results be positive, ensuring immediate patient benefit. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date.",To be made available at a later date,,,National Institute for Health Research,South London and Maudsley NHS Foundation Trust; King's College London,grid.37640.36,http://dx.doi.org/10.13039/501100000272,01/12/2024,01/02/2020,30/11/2024,12/10/2020,31/07/2022,23/11/2020,03/08/2020,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,Interventional randomized controlled trial,"Post-traumatic stress disorder, schizophrenia, psychosis Mental and Behavioural Disorders Post-traumatic stress disorder, schizophrenia, psychosis",Mental and Behavioural Disorders,,government organisation,Hospital/treatment centre; University/education,Randomised controlled trialRandomised controlled trial,Community,Treatment,Behavioural,,,Patient,Adult,Both,300,
1233,ISRCTN17896927,Encouraging behavior to reduce the spread of COVID-19,1312013102,"No ethics approval required, Yale University Human Research Protection Program (25 Science Park, 150 Munson Street, 3rd Floor, New Haven, CT 06511; no telephone number provided; HRPP@yale.edu), ref: 1312013102",United States of America,,"Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The datasets generated during and/or analysed during the current study will be stored in a publically available repository. The underlying anonymous study microdata, documentation of the survey, and statistical analysis code will be posted on the replication archive required by the journal in which the resulting paper is published, with public access, or at the Harvard Dataverse if the journal does not require a specific archive to be used. The material will be publicly available for anyone to download. Consent was obtained for data sharing. Additional documents available at: https://osf.io/vpafh/?view_only=5b9b78b1162d4fa091b8f569199e664f",Stored in repository,,2020 non-peer-reviewed results in preprint https://doi.org/10.21203/rs.3.rs-96261/v1 (added 19/03/2021),Investigator initiated and funded,Yale University,Missing GRID,,17/07/2021,01/05/2020,24/07/2020,17/07/2020,24/07/2020,19/03/2021,27/07/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Interventional randomized controlled trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,,University/education,Randomised controlled trialRandomised controlled trial,Internet,Prevention,Behavioural,,,All,Adult,Both,3000,
1239,ISRCTN13035264,Adaptive COVID-19 treatment trial in the EU & UK,"DMID Protocol Number: 20-0006, INSIGHT Protocol Number: 010, UPHR - CPMS 45521, IRAS 281800","Approved 26/03/2020, South Central - Hampshire B Research Ethics Committee (Previously Southampton B IRB00005934) (Level 3 Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT, UK; +44 (0)207 104 8045, +44 (0)207 104 8057, +44 (0)207 104 8054; hampshireb.rec@hra.nhs.uk), REC ref: 20/SC/0154",Denmark; Greece; United Kingdom,,Planned publication in a high-impact peer-reviewed journal by September 2020. IPD sharing statement The data-sharing plans for the current study are unknown and will be made available at a later date,To be made available at a later date,,2020 results in https://pubmed.ncbi.nlm.nih.gov/32445440/ (added 14/04/2021),"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases",University of Minnesota,grid.17635.36,http://dx.doi.org/10.13039/100015691,01/09/2020,17/03/2020,30/08/2020,31/03/2020,30/06/2020,14/04/2021,24/07/2020,Completed,No longer recruiting,Retrospectively registered,2020-001052-18,NCT04280705,Multicenter adaptive randomized double-blind placebo-controlled trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,government organisation,University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,Remdesivir,Phase III,Patient,Adult,Both,400,1063.0
1251,ISRCTN14212905,Understanding how COVID-19 leads to respiratory failure in COVID-19 positive patients,"20/SS/0060, IRAS 282934","Approved 03/07/2020, Scotland A REC (2nd Floor Waverley Gate, 2-4 Waterloo Place, Edinburgh, EH1 3EG, UK; +44 (0)131 4655678; manx.neill@nhslothian.scot.nhs.uk), ref: 20/SS/0066",United Kingdom,,"Scientific publications and the sharing of clinical data generated as part of this trial is crucial to better understanding COVID-19 and developing new treatments. As such, the results of each nested study detailed in the relevant appendices will be published as soon as the treatment arm has finished recruitment, data has been cleaned and any outstanding patient safety follow-ups completed. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date.",To be made available at a later date,,,Life Arc,University of Edinburgh; NHS Lothian,grid.4305.2; grid.39489.3f,,10/10/2021,01/03/2020,01/12/2021,03/07/2020,22/06/2021,17/03/2021,22/07/2020,Ongoing,No longer recruiting,Retrospectively registered,2020-002230-32,NCT04473053,Phase II interventional randomized controlled single centre,Prevention of lung injury in patients with COVID-19 (SARS-CoV-2 infection) Respiratory COVID-19 (SARS-CoV-2 infection),Respiratory,,,University/education; Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,"Nafamostat, TD139",Phase II,Patient,Adult,Both,100,
1255,ISRCTN10207947,Study of chloroquine/hydroxychloroquine and coronavirus disease (COVID-19) in the healthcare setting,"CPMS 45731, IRAS 282109","Approved 18/03/2020, Oxford Tropical Research Ethics Committee (OxTREC) (Research Services, University of Oxford, University Offices, Wellington Square, Oxford OX1 2JD; +44(0)1865 (2)82106; oxtrec@admin.ox.ac.uk), ref: 25-20",Benin; Ethiopia; Indonesia; Kenya; Laos; Mali; Niger; Pakistan; Thailand; United Kingdom; Zambia,,"All publications will abide by the International Committee of Medical Journal Editors (ICMJE) recommendations of the role of authors and contributors. The results of the study will be summarised in lay language, in both English and the language(s) commonly spoken at the study sites, and disseminated to key stakeholders, user communities and caretakers of study participants. IPD sharing statement: With the participant’s consent, clinical data and results from blood analyses stored in the database may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future. Data generated from this study will adhere to the 2016 Statement on data sharing in public health emergencies (https://wellcome.ac.uk/press-release/statement-data-sharing-public-health-emergencies).",Available on request,,,Wellcome Trust; Bill and Melinda Gates Foundation; Mastercard Foundation,University of Oxford,grid.4991.5,http://dx.doi.org/10.13039/100004440; http://dx.doi.org/10.13039/100000865; http://dx.doi.org/10.13039/501100015278,31/12/2021,29/04/2020,30/12/2021,29/04/2020,30/12/2021,03/06/2021,21/07/2020,Ongoing,Recruiting,Retrospectively registered,2020-001441-39,NCT04303507,"Multi-centre double-blind, randomized placebo-controlled trial",COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection) in healthcare workers,Infections and Infestations,,private sector organisationprivate sector organisationprivate sector organisation,University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Drug,"Current drug name(s) as of 03/06/2021: Chloroquine and hydroxychloroquine will be in the dose of 155 mg chloroquine base (250 mg of chloroquine phosphate or 200 mg of hydroxychloroquine sulphate) It is expected that chloroquine will be used in Asian sites and hydroxychloroquine in Europe and Africa, specific drug allocation will be determined by each participating country. Hydroxychloroquine sulphate will be used in the UK. Previous drug name(s): Chloroquine and hydroxychloroquine will be in the dose of 155 mg chloroquine base (250 mg of chloroquine phosphate or 200 mg of hydroxychloroquine sulphate) It is expected that chloroquine will be used in Asian sites and hydroxychloroquine in Europe, specific drug allocation will be determined by each participating country. Hydroxychloroquine sulphate will be used in the UK.",Phase III,Healthy volunteer,Adult,Both,40000,
1256,ISRCTN14241621,Trial of inhaled anti-viral (SNG001) for SARS-CoV-2 (COVID-19) infection,"SG016, IRAS 281317","Approved 17/03/2010, North West - Haydock Research Ethics Committee (3rd Floor - Barlow House, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)207 104 8012; haydock.rec@hra.nhs.uk), ref: 20/NW/0168",United Kingdom,,1. Planned publication in a high-impact peer-reviewed journal 2. Internal report 3. Conference presentation 4. Publication on website 5. Other publications 6. Submission to regulatory authorities No additional documents will be made available IPD sharing statement The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.,Other,,2020 pilot results in hospitalised patients in https://doi.org/10.1016/S2213-2600(20)30511-7 (added 26/11/2020),Synairgen Research Ltd,Synairgen Research Ltd,Missing GRID,,31/05/2022,05/03/2020,31/05/2021,30/03/2020,30/04/2021,26/11/2020,21/07/2020,Completed,No longer recruiting,Retrospectively registered,2020-001023-14,NCT04385095,Multicentre interventional double-blinded randomised controlled trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,Industry,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,Interferon beta-1a,Phase II,Patient,Adult,Both,220,
1260,ISRCTN67000769,An international platform trial for severely ill patients with community-acquired pneumonia or COVID-19,"CPMS 38197, IRAS 237150","Approved 30/04/2018, Surrey Borders REC (Health Research Authority, Skipton House, 80 London Road, London, SE1 6LH, UK; +44 (0)207 104 8104, +44 (0)207 104 8134, +44 (0)207 972 2568; surreyborders.rec@hra.nhs.uk), REC ref: 18/LO/0660",Australia; Belgium; Canada; Croatia; Finland; France; Germany; Hungary; Ireland; Netherlands; New Zealand; Portugal; Saudi Arabia; Spain; United Kingdom; United States of America,,"The protocol has a modular structure and the core protocol and all domain-specific appendices are available on the ICNARC website: https://www.remapcap.org/protocol-documents. Planned publications in a high-impact peer-reviewed journal. The researchers will publish results on individual domains and treatments as soon as possible, once individual statistical triggers are met. IPD sharing statement The data-sharing plans for the current study are unknown and will be made available at a later date.",To be made available at a later date,,2020 protocol in https://pubmed.ncbi.nlm.nih.gov/32267771/ (added 16/07/2020) 2020 results for hydrocortisone in https://pubmed.ncbi.nlm.nih.gov/32876697/ (added 03/09/2020) 2021 results for tocilizumab and sarilumab in preprint https://doi.org/10.1101/2021.01.07.21249390 (added 08/01/2021) 2021 results for tocilizumab and sarilumab in https://doi.org/10.1056/NEJMoa2100433 (added 18/03/2021),European Commission,University Medical Center Utrecht,grid.7692.a,http://dx.doi.org/10.13039/501100000780,31/12/2024,11/04/2016,31/12/2023,28/05/2019,13/02/2022,06/07/2021,20/07/2020,Ongoing,Recruiting,Retrospectively registered,2015-002340-14,NCT02735707,"Randomized; Interventional; Design type: Treatment, Process of Care, Drug","COVID-19 (SARS-CoV-2 infection), influenza and pneumonia Infections and Infestations Influenza and pneumonia",Infections and Infestations,,government organisation,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,"Ceftriaxone, moxifloxacin or levofloxacin, piperacillin-tazobactam, ceftaroline, amoxicillin-clavulanate, hydrocortisone, azithromycin or clarithromycin or erythromycin or roxithromycin",Not Applicable,Patient,Adult,Both,6000,4400.0
1262,ISRCTN60069084,Effect of N-acetylcysteine on COVID-19 treatment,E-20-4934,"1. Approved 30/06/2020 by King Saud University Medical City Institutional Review Board (3rd Floor Room 317, Block 22 (near Theatre C), King Saud University College of Medicine and King Khalid University Hospital, PO Box 7805 Riyadh, 11472 K.S.A.; +966 (0)11 469 1531; +966 (0)11 469 1532; rdeocampo@ksu.edu.sa; irb.medksu@hotmail.com), ref: E-20-4934 2. Approved 20/07/2020, Ministry of Health - Kingdom of Saudi Arabia-Central Institutional Review Board (PO Box 7805 Riyadh, 11472 K.S.A; +966 (0)11 212 5555 ext 4337 1; haziz@moh.gov.sa), ref: E-20-146E 3. Approved 20/07/2020, Ministry of Health - Sultanate Oman Research and ethical review and approval center (PO Box 393, Postal Code 100, Muscat, Oman; +968 22357254; mohrerac@gmail.com), ref: MOH/CSR/20/23522",Oman; Saudi Arabia,,"Planned publication in a high-impact peer-reviewed journal. IPD sharing statement The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Baian Alabdulbaqi (balabdulbaqi@ksu.edu.sa). All of the individual participant data collected during the trial, after identification, will be available immediately following publication with no end date and can be used for any purpose. Analysis Plan, Informed Consent Form, Clinical Study Report, and Analytic Code will be available for anyone who wishes to access the data.",Available on request,,,Prince Naif Bin Abdulaziz Health Research Center,King Saud Medical City,Missing GRID,,01/10/2022,21/03/2020,01/10/2021,01/09/2020,01/09/2021,03/08/2020,19/07/2020,Ongoing,Recruiting,Prospectively registered,Nil known,NCT04455243,Adaptive pilot double-blinded randomized placebo-controlled multi-center clinical trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,N-Acetylcysteine (NAC),Phase III/IV,Patient,Adult,Both,1180,
1286,ISRCTN48734830,Using the blood pressure medication losartan to improve outcomes for patients with SARS CoV-2,Nil known,"Approved 18/05/2020, Swedish Ethical Review Authority (Etikprövningsmyndigheten, Box 2110, 750 02, Uppsala, Sweden; +46 10-475 08 00; registrator@etikprovning.se), ref: 2020-02185",Sweden,,Planned publication in peer-reviewed journal. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date.,To be made available at a later date,,,Vetenskapsrådet,Stockholm South General Hospital,grid.416648.9,http://dx.doi.org/10.13039/501100004359,01/05/2022,21/04/2020,31/01/2022,03/08/2020,31/12/2021,16/02/2021,10/07/2020,Ongoing,Recruiting,Prospectively registered,2020-002040-22,Nil known,Open-label pragmatic phase IV randomized controlled trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,government organisation,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,Losartan,Phase IV,Patient,Adult,Both,750,
1291,ISRCTN10378358,"Reducing the risk of COVID-19 spread in hospitals, by stopping droplets from spreading",IRAS 285515,Not provided at time of registration,United Kingdom,,"Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Request to richard.newsom@port.ac.uk – from website: https://researchportal.port.ac.uk/portal/ - for ten years – no personal patient data will be retained, but consent will be taken.",Available on request,,,UK Research and Innovation,University of Portsmouth; Queen Alexandra Hospital,grid.4701.2; grid.415470.3,http://dx.doi.org/10.13039/100014013,01/12/2022,15/06/2020,01/03/2022,01/11/2020,01/12/2021,14/09/2020,08/07/2020,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,Multi-centre randomized controlled trial,Patients undergoing AGP Infections and Infestations,Infections and Infestations,,,University/education; Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Device,Plastic sheet 2 x 3 m,Not Applicable,Patient,Adult,Both,400,
1324,ISRCTN68675756,Psychological intervention to improve the mental health of patients with COVID-19,Nil known,"Approved 04/02/2020, Ethics Committee of the First Affiliated Hospital of Bengbu Medical College (No.287, Changhuai Road, Bengbu City, Anhui Prov, China, 233000; +86 (0)552 3086046; no email address), ref: BYYFY-2020KY10",China,,"Planned publication in a high-impact peer-reviewed journal IPD sharing statement The datasets generated during and/or analysed during the current study are not expected to be made available as it is stipulated in the informed consent signed with the patient that any information of the participants will not be disclosed, and the dataset compiled for this study will be kept and stored by the first author.",Not expected to be available,,2020 results in https://pubmed.ncbi.nlm.nih.gov/33192723/ (added 17/11/2020),Bengbu Medical College,Bengbu Medical College,Missing GRID,http://dx.doi.org/10.13039/501100007924,01/09/2020,01/02/2020,22/03/2020,10/02/2020,22/03/2020,17/11/2020,01/07/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Interventional randomised controlled trial,"Depression, anxiety and stress in patients with COVID-19 (SARS-CoV-2 infection) Mental and Behavioural Disorders",Mental and Behavioural Disorders,,government organisation,University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Behavioural,,,Patient,Adult,Both,93,93.0
1369,ISRCTN54917435,Could prone positioning increase lung function for patients with severe COVID-19 infection?,1,"Approved 20/05/2020, Swedish Ethical Review Authority (Box 2110, 750 02 Uppsala, Sweden; +46 (0)10 475 08 00; registrator@etikprovning.se), ref: 2020-02743",Sweden,,"Publication in an international peer-reviewed journal IPD sharing statement Measurements and recordings concerning ordinary health care are stored in the EHR according to Swedish healthcare legislation. For measurements recorded in preprinted protocols (CRF) the protocols will be stored in an Investigator Site File in a locked room before being transformed into a database via webform (OpenClinica). All digital data is stored for at least 10 years after publication in a password-protected server. Participants in the trial group will have access to the data. Every study participant can request to take part of only their own data. Data on an aggregated, not individual, level will be published in a peer-reviewed journal, this with consent from participants. On request of authorities, if any doubt’s of the trail’s integrity according to GCP and becoming subject for investigation, data will be shared without consent from participants. No other sharing is allowed.",Not expected to be available,,2021 results in https://pubmed.ncbi.nlm.nih.gov/34127046/ (added 17/06/2021),Akademiska Sjukhuset,Uppsala County Council,Missing GRID,http://dx.doi.org/10.13039/501100005423,30/10/2021,20/04/2020,25/06/2021,25/06/2020,08/06/2021,17/06/2021,15/06/2020,Completed,No longer recruiting,Prospectively registered,Nil known,Nil known,Multicentre open labelled interventional randomized controlled study with two parallel groups,Respiratory function in patients with respiratory failure due to COVID-19 infection Infections and Infestations,Infections and Infestations,,private sector organisation,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Other,,,Patient,Adult,Both,240,75.0
1372,ISRCTN89951424,A phase III study to investigate a vaccine against COVID-19,COV003,"1. Approved 03/06/2020, The National Commission for Research Ethics (Comissão Nacional de Ética em Pesquisa (CONEP), SRTVN 701, Via W 5 Norte, lote D - Edifício PO 700, 3º andar, Asa Norte CEP, Brasilia, 70.719-040, Brazil; +55 61 3315-5877; conep@saude.gov.br), ref: 4068113 2. Approved 12/06/2020, Oxford Tropical Research Ethics Committee (OxTREC) (University of Oxford, Research Services, University Offices, Wellington Square, Oxford, OX1 2JD, UK; +44 (0) 1865 (2)82106; oxtrec@admin.ox.ac.uk), ref: 36-20",Brazil,,"The Investigators will be involved in reviewing drafts of the manuscripts, abstracts, press releases and any other publications arising from the study. Data from the study may also be used as part of a thesis for a PhD or MD. Planned publication in a high-impact peer-reviewed journal. IPD sharing statement The data sharing plans for the current study are unknown and will be made available at a later date.",To be made available at a later date,,2020 interim results in https://pubmed.ncbi.nlm.nih.gov/33306989/ (added 09/12/2020) 2021 results in https://pubmed.ncbi.nlm.nih.gov/33617777/ (added 23/02/2021),University of Oxford,University of Oxford,grid.4991.5,,31/07/2022,01/05/2020,31/12/2021,15/06/2020,31/12/2020,23/02/2021,11/06/2020,Ongoing,No longer recruiting,Prospectively registered,Nil known,Nil known,"Single-blind randomised efficacy, safety and immunogenicity study",COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Biological/Vaccine,"ChAdOx1 nCoV-19 vaccine, MenACWY vaccine",Phase III,Mixed,Mixed,Both,10300,
1384,ISRCTN94091479,Behavioural Activation in Social IsoLation (BASIL): Benefiting from activities to improve your mood while you are socially isolating,"CPMS 45854, IRAS 249030","Approved 23/04/2020, Yorkshire and The Humber – Leeds West Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 104 8018; leedswest.rec@hra.nhs.uk), ref: 18/YH/0380 (approved as substantial amendment 02 under existing MODS research programme)",United Kingdom,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The data sharing plans for the current study are unknown and will be made available at a later date.,To be made available at a later date,,,National Institute for Health Research Programme Grants for Applied Research,"Tees, Esk and Wear Valleys NHS Foundation Trust",grid.439606.e,,31/12/2022,01/04/2020,31/12/2021,15/06/2020,30/09/2020,09/06/2020,09/06/2020,Ongoing,No longer recruiting,Prospectively registered,Nil known,Nil known,A multicentre two arm parallel group individually pilot randomised controlled trial with embedded qualitative evaluation,Depression and loneliness in older adults with long-term physical health conditions Mental and Behavioural Disorders,Mental and Behavioural Disorders,,,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,GP practices,Treatment,Behavioural,,,Patient,Senior,Both,100,
1397,ISRCTN59048638,Sulodexide in the treatment of COVID-19,Nil known,"Approved 28/05/2020 Comite de Etica e Investigacion Facultad de Medicina Mexicali (Coordinacion de posgrado e Investigacion, Av Alvaro Obregon y Julian Carrillo s-n Col. Nueva CP 21100; +52 686 551 9497; cei.fm@uabc.edu.mx), ref: none provided",Mexico,,"Journal publication, oral meeting presentation. IPD sharing statement: All data generated or analysed during this study will be included in the subsequent results publication.",Other,See additional files (ISRCTN59048638_BasicResults_04Dec2020),2021 results in https://pubmed.ncbi.nlm.nih.gov/33677827/ (added 08/03/2021),Investigator initiated and funded; alfasigma Mexico,CLINEDEM,Missing GRID,,12/12/2020,15/04/2020,30/11/2020,15/06/2020,06/08/2020,08/03/2021,04/06/2020,Completed,No longer recruiting,Prospectively registered,Nil known,Nil known,Prospective interventional cohort study,COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,GP practices,Treatment,Drug,Sulodexide,Not Applicable,Patient,Adult,Both,200,243.0
1399,ISRCTN17072692,Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women,IRAS 279315,"Approved 11/06/2020, North East - York Research Ethics Committee (NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle upon Tyne, NE2 4NQ, UK; +44 (0)207 1048091; no email provided), 20/NE/0169",United Kingdom,,"The preparation of a manuscript for publication in a peer-reviewed professional journal or an abstract for presentation, oral or written, to a learned society or symposium will be discussed on the TMG calls and with the PPI Advisory Group. IPD sharing statement The data-sharing plans for the current study are unknown and will be made available at a later date.",To be made available at a later date,,,Medical Research Council; UK Research and Innovation,Imperial College London,grid.7445.2,http://dx.doi.org/10.13039/501100000265; http://dx.doi.org/10.13039/100014013,31/07/2022,01/04/2020,31/07/2021,16/06/2020,31/10/2020,27/07/2020,04/06/2020,Ongoing,No longer recruiting,Prospectively registered,2020-001646-20,Nil known,Randomised controlled trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,government organisationprivate sector organisation,University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Biological/Vaccine,LNP-nCoVsaRNA,Phase I,Healthy volunteer,Adult,Both,320,
1402,ISRCTN33578935,To study the treatment of COVID-19 with severe viral pneumonia by using purified stem cell exosomes,89081,"Approval pending, Ethikkommission der Universität Ulm (Inst. für Geschichte, Theorie und Ethik der Medizin, Parkstraße 11, 3. OG, 89073 Ulm, Germany; +49 (0)731 500 33720; no email provided), ref: 123/20",Germany,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: All data generated or analysed during this study will be included in the subsequent results publication.,Other,,,Ulm University Hospital,Kimera Labs,grid.410712.1,,01/08/2020,26/04/2020,31/12/2020,01/06/2020,31/12/2020,08/06/2020,02/06/2020,Completed,No longer recruiting,Retrospectively registered,2020-002326-90,Nil known,Interventional randomized parallel trial,Hypercytokinemia in patients with COVID-19 and severe respiratory distress syndrome (SARS) due to CoV-2 infection Infections and Infestations,Infections and Infestations,,,Hospital/treatment centre,Randomised parallel trialRandomised parallel trial,Hospitals,Treatment,Biological/Vaccine,XoGlo,Phase II,Patient,Adult,Both,64,
1416,ISRCTN99248812,Peer support training for adolescents during the COVID-19 outbreak,R69810/RE001,"Approved 22/05/2020, University of Oxford, Medical Sciences Interdivisional Research Ethics Committee (Research Services, University of Oxford, Wellington Square, Oxford, OX1 2JD, UK; +44(0)1865 616577; ethics@medsci.ox.ac.uk), ref: R69810/RE001",United Kingdom,,1. The full study protocol is not yet available but will be uploaded to the registration prior to study completion. 2. Planned publication of the study results in a high-impact peer-reviewed journal. IPD sharing statement The data-sharing plans for the current study are unknown and will be made available at a later date.,To be made available at a later date,,,"Economic, Social, Cultural, & Environmental Impacts of COVID-19: Urgent Response Fund",University of Oxford,grid.4991.5,,31/12/2020,01/04/2020,10/07/2020,30/05/2020,05/06/2020,28/08/2020,29/05/2020,Completed,No longer recruiting,Prospectively registered,Nil known,Nil known,Pilot randomised controlled trial,Peer support during the COVID-19 outbreak Not Applicable,Not Applicable,,,University/education,Randomised controlled trialRandomised controlled trial,Internet,Quality of life,Behavioural,,,Healthy volunteer,Child,Both,100,100.0
1425,ISRCTN12107048,Supporting weight management during COVID-19,Version 2.0 18.05.2020,"Approved 24/04/2020, Cambridge Psychology Research Ethics Committee (School of the Biological Sciences, 17 Mill Lane, Cambridge, UK; +44 (0)1223 766894; Cheryl.Torbett@admin.cam.ac.uk), ref: PRE.2020.049 COV19",United Kingdom,,"Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The datasets generated during and/or analysed during the current study will be available upon request from MRC Epidemiology Unit, University of Cambridge. Dr Amy Ahern, amy.ahern@mrc-epid.cam.ac.uk Data will become available following analyses completed by the PI and collaborators. Data request forms will need to be completed and sent to the PI for discussion with the other Principle Investigators. Consent will be obtained from participants and all data anonymised.",Available on request,,,National Institute for Health Research,University of Cambridge,grid.5335.0,http://dx.doi.org/10.13039/501100000272,30/04/2022,07/04/2020,31/12/2021,08/06/2020,07/09/2020,15/06/2021,28/05/2020,Ongoing,No longer recruiting,Prospectively registered,Nil known,Nil known,Pragmatic randomized single-blind parallel-group two-arm single-centre trial,"Overweight and Obesity Nutritional, Metabolic, Endocrine Obesity","Nutritional, Metabolic, Endocrine",,government organisation,University/education,Randomised parallel trialRandomised parallel trial,Home,Prevention,Behavioural,,,Patient,Adult,Both,360,388.0
1434,ISRCTN40302986,Does ivermectin cure and/or prevent COVID-19?,Nil known,"Approved 07/06/2020, Lagos University Teaching Hospital ethics committee (Prof. Njideka Okubadejo, Department of Medicine, College of Medicine, University of Lagos, Lagos, Nigeria; +234 (0)1 5850737, 5852187; hrecluth@gmail.com, njide_okubadejo@yahoo.com), ref: NAF/DER/CT/IVERCOVID/2020",Nigeria,,"The researchers will make additional documents including the protocol available as soon as they are finalised. The researchers hope to publish their results in peer-reviewed journals such as the Nigerian Medical Journal, National Postgraduate medical journal and the Lancet. They will also describe their results to the lay public through the news media. IPD sharing statement The datasets generated during and/or analysed during the current study are/will be available upon request from Prof. Femi Babalola (Bablo57@gmail.com). Anyone who is interested in analyzing the data is welcome to have a look at it provided the original authors are included in whatever publication emanates from such.",Available on request,,2021 results in https://doi.org/10.1093/qjmed/hcab035 (added 23/03/2021),Rachel Eye Center,Lagos University Teaching Hospital,grid.411283.d,,10/11/2020,23/04/2020,06/10/2020,22/06/2020,22/09/2020,23/03/2021,26/05/2020,Completed,No longer recruiting,Prospectively registered,Nil known,Nil known,Randomised controlled trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,Ivermectin,Phase III,Patient,All,Both,45,62.0
1435,ISRCTN11384058,"A collaborative pilot study to monitor and optimise access to urgent surgery during the period of reduced resources in Genoa, Italy caused by the COVID-19 pandemic, using a bespoke referral process and the SWALIS 2020 model to prioritise surgery by clinical urgency and waiting time",CoV-2-GOASUR-SWALIS2020-FP1,"Approved 18/03/2020, Italian Liguria Regional Ethics Committee (Segreteria Amministrativa del Comitato Etico Regionale, Ospedale Policlinico San Martino – IRCCS, Largo Rosanna Benzi, 10 – 16132 Genoa; Tel: +39 (0)10 555 4214 / 4212 / 4213 / 4215 / 4216; comitato.etico@hsanmartino.it), ref: 233/2020",Italy,,"1. The study protocol and the statistical analysis plan will be available at publication 2. International journals and meetings, study website (in progress) IPD sharing statement The datasets generated during and/or analysed during the current study are/will be available upon request from Mr Roberto Valente (roberto.valente@hsanmartino.it) and Dr Stefano Di Domenico (Stefano.didomenico@hsanmartino.it). The dataset is in an MS Access TM format, and can be anonymised to any level required, as allowed by the Liguria Ethics Committee. The dataset will be made available 3 months after study completion, for 12 months, extendable. Any sharing request will be submitted to the Liguria Ethics Committee for approval.",Available on request,,2020 non-peer-reviewed results in preprint https://doi.org/10.1101/2020.07.21.20157719 (added 17/03/2021) 2020 results in https://pubmed.ncbi.nlm.nih.gov/33640936/ (added 16/04/2021) 2021 results in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845497/ (added 17/03/2021),Liguria Health System,Policlinico San Martino Genoa; Azienda Liguria Sanità (ALiSa),Missing GRID,,01/06/2020,25/03/2020,15/06/2020,01/04/2020,10/05/2020,16/04/2021,26/05/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,"Multicentre feasibility (2 weeks) and pilot (4 weeks), single-cohort, before-after, pragmatic interventional service improvement research study","The severe imbalance and variable demand/supply for elective surgery during the COVID-19 pandemic, determined by postponements, backlog and ""hidden"" waiting lists Not Applicable",Not Applicable,,,Hospital/treatment centre; Government,"Single-cohort, before-after, pragmatic interventional service improvement researchSingle-cohort, before-after, pragmatic interventional service improvement research",Hospitals,Other,Other,,,Patient,Adult,Both,300,240.0
1441,ISRCTN15254871,Online parent training for reducing parenting stress during the coronavirus pandemic,2020/185,"Approved 12/05/2020, Faculty of Education and Psychology, Research Ethics Committee of the Eötvös Loránd University (Izbella 46, Budapest 1064, Hungary; + (36-1) 461-2600 / 5614; molnar.mark@ppk.elte.hu), ref: 2020/185",Hungary,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: All data generated or analysed during this study will be included in the subsequent results publication.,Other,,,Eötvös Loránd University,Heim Pál National Pediatric Institute LÉTRA Foundation,Missing GRID,,15/01/2021,06/04/2020,15/12/2020,18/05/2020,30/11/2020,21/05/2020,23/05/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Interventional randomized controlled study,Parental stress during COVID-19 pandemic Not Applicable,Not Applicable,,,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Internet,Prevention,Behavioural,,,Healthy volunteer,Adult,Both,300,
1443,ISRCTN13447477,A pilot study of the ability of povidone-iodine (PVP-I) 0.5% aqueous solution oral/nasal spray and mouthwash to kill the SARS-CoV-2 virus in people with COVID-19,IRAS 283182,"Approved 15/06/2020, NHS Health Research Authority (Health Research Authority, Skipton House, 80 London Road, London, SE1 6LH, UK; +44 (0)20 7972 2545; hra.approval@nhs.net), ref: 20/HRA/2711",United Kingdom,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: All data generated or analysed during this study will be included in the subsequent results publication.,Other,,,"British Association of Oral and Maxillofacial Surgeons; Royal Surrey County Hospital Charitable Fund; Surrey Perioperative, Anaesthesia & Critical Care Collaborative Research Group",Royal Surrey County Hospital NHS Foundation Trust,grid.412946.c,,30/11/2020,15/03/2020,28/02/2021,04/11/2020,31/12/2020,23/10/2020,22/05/2020,Completed,No longer recruiting,Prospectively registered,Nil known,Nil known,Single-arm non-randomised open-label uncontrolled interventional study,COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,,Hospital/treatment centre,Non randomised studyNon randomised study,Hospitals,Treatment,Drug,Povidone iodine 0.5%,Not Applicable,Patient,Adult,Both,22,
1451,ISRCTN50212645,"COG-UK Project Hospital-Onset COVID-19 Infections (HOCI) Study: How effective are infection
prevention and control measures that are informed by genetic analysis of coronavirus (rapid and
standard) at preventing COVID-19 in NHS hospitals?","CTU/2020/353, IRAS 283014","Approved 23/04/2020, East of England - Cambridge South Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 104 8065; cambridgesouth.rec@hra.nhs.uk), ref: 20/EE/0118",United Kingdom,,"Protocol and protocol paper will be uploaded as soon as available. Study results will be published in peer-reviewed scientific journals, in internal reports and submitted to regulatory authorities. The researchers will not publish identifiable data - anonymity will be maintained. IPD sharing statement The data-sharing plans for the current study are unknown and will be made available at a later date (due to the requirement for further legal clarity in relation to the upcoming expiry of the COPI notice with regards to the trial team’s obligations under the United Kingdom data protection regulation). Updated 26/04/2021: The datasets generated during and/or analysed during the current study will be stored in a publicly available repository. The terms of the funding requires the COG-UK HOCI study dataset to be shared on CSDR (https://clinicalstudydatarequest.com/) or an equivalent data-sharing platform so that the data may be reused by other researchers. This will be done within 6 months of public reporting of results.",Stored in repository,,,COG-UK Consortium; UK Research and Innovation; Medical Research Council,University College London,grid.83440.3b,http://dx.doi.org/10.13039/100014013; http://dx.doi.org/10.13039/501100000265,31/08/2021,17/03/2020,31/07/2021,01/06/2020,31/05/2021,26/04/2021,20/05/2020,Ongoing,No longer recruiting,Prospectively registered,Nil known,NCT04405934,Phase III prospective interventional cohort superiority study,Hospital-onset COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,private sector organisationgovernment organisation,University/education,Non randomised studyNon randomised study,Hospitals,Prevention,Other,,,Patient,All,Both,2380,
1463,ISRCTN21363594,Therapeutic plasma exchange (removal of the non-cell portion of blood) in critically ill adult patients with serious SARS CoV-2 disease (COVID-19),KSMC-IRB-H1R1-29-Apr20-01,"Approved 29/04/2020, King Saud Medical City Riyadh Institutional Review Board (King Saud Medical City, Riyadh, Saudi arabia; +966 435 5555 Ext 2345; irb@ksmc.med.sa), ref: H-01-R-053, IORG0010374, H1RI-29-Apr20-01",Oman; Saudi Arabia; United Arab Emirates,,"We are aiming to publish our preliminary results as soon as possible as the study is currently running. We are expecting our first publication to be ready soon hence we wish to register the trial as soon as possible. IPD sharing statement: The datasets generated during and/or analysed during the current study will be available upon request from the principal investigator Dr Fahad Faqihi, dr.faqihi677@gmail.com.",Available on request,,2020 protocol in https://doi.org/10.1186/s13063-020-04454-4 (added 10/06/2020),King Saud Medical City,King Saud Medical City,grid.415998.8,,30/07/2020,01/04/2020,29/12/2020,01/05/2020,29/10/2020,10/06/2020,18/05/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Pilot interventional randomized controlled trial,Serious and life-threatening COVID-19 requiring ICU admission Infections and Infestations SARS CoV-2 infection,Infections and Infestations,,,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Procedure/Surgery,,,Patient,Adult,Both,80,
1468,ISRCTN11188345,A therapeutic study in pre-ICU patients admitted with coronavirus using repurposed drugs ,CCTU0303; IRAS 282213,"Approved 04/05/2020, East of England - Cambridge Central Research Ethics Committee (Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 104 8388; cambridgecentral.rec@hra.nhs.uk), ref: 20/EE/0135",United Kingdom,,"Planned publication in a high-impact peer-reviewed journal. The protocol (not peer reviewed) available at the study website. Ownership of the data arising from this trial resides with the trial team and the sponsor. On completion of the trial the data will be analysed and tabulated and a Final Trial Report prepared. However, given the nature of this international pandemic, preliminary data may be reported prior to the completion the study, or if interim analyses are adequate for dissemination of critical safety or efficacy data. Any bloods done as part of the protocol or as part of observational studies will need to adhere to the pre-agreed publications policy of the TACTIC core research trial team. The sponsor will provide, if practicable, advanced notice of any publications to Alexion Pharma UK. At conclusion of the study a fully anonymised dataset will be placed in the public domain. Data sharing within a federated consortium of UK investigators across the four nations will be adopted. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date.",To be made available at a later date,,2020 protocol in https://pubmed.ncbi.nlm.nih.gov/32641154/ (added 10/07/2020),Eli Lilly and Company; Alexion Pharmaceuticals,Cambridge University Hospitals NHS Foundation Trust,Missing GRID,http://dx.doi.org/10.13039/100004312; http://dx.doi.org/10.13039/100006396,01/05/2023,01/05/2020,01/05/2022,07/05/2020,01/07/2021,03/11/2020,15/05/2020,Ongoing,No longer recruiting,Retrospectively registered,2020-001354-22,NCT04390464,Randomised parallel arm open-label multicentre Phase IV platform trial,Late stage 1/stage 2 COVID-19-related disease COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,private sector organisationprivate sector organisation,Hospital/treatment centre,Randomised parallel trialRandomised parallel trial,Hospitals,Treatment,Drug,"Baricitinib, Ravulizumab",Phase IV,Patient,Adult,Both,375,
1472,ISRCTN88057279,Preventative treatment for patients at risk of COVID-19 infection (PROTECT),"CCTU0307, IRAS 282317","Current ethics approval as of 27/07/2020: Approved 02/06/2020, East of England - Cambridge East Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS; +44 (0)207 104 8102; CambridgeEast.REC@hra.nhs.uk), ref: 20/EE/0146 _____ Previous ethics approval: Not provided at time of registration",United Kingdom,,"All publications will be approved by the PROTECT steering group. Reporting of results will be through publication of manuscripts in peer-reviewed journals and oral or poster presentations at relevant National or International meetings. As COVID-19 represents an emerging challenge, interim analyses may be made available via pre-print repositories ahead of publication in peer-reviewed journals or meetings. Audit datasets will be disseminated to relevant organisations with the agreement of the PROTECT steering group. Important findings may be communicated through local or National media as approved by the PROTECT steering group and Sponsor Communications teams. All publications will be approved by the PROTECT SG. Reporting of results will be through publication of manuscripts in peer-reviewed journals and oral or poster presentations at relevant National or International meetings. As COVID-19 represents an emerging challenge, interim analyses may be made available via pre-print repositories ahead of publication in peer-reviewed journals or meetings. Important findings may be communicated through local or National media as approved by the PROTECT steering group and Sponsor Communications teams. IPD sharing statement: The datasets generated during and/or analysed during the current study are available on reasonable request from add-tr.protect@nhs.net",Available on request,,,April Trust,Cambridge University Hospitals NHS Foundation Trust; University of Cambridge,grid.24029.3d; grid.5335.0,,01/12/2025,03/04/2020,03/05/2025,01/10/2020,01/12/2024,25/03/2021,14/05/2020,Ongoing,Recruiting,Prospectively registered,2020-002016-48,NCT04389359,Open-label multi-centre randomized controlled trial,"COVID-19 (SARS-CoV-2 infection) in dialysis, vasculitis, and kidney transplant patients Infections and Infestations",Infections and Infestations,,,Hospital/treatment centre; University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Drug,Hydroxychloroquine sulfate,Phase II/III,Patient,Adult,Both,500,
1490,ISRCTN85216856,Using blood plasma to develop passive immunity to coronavirus in Ecuador,Nil known,"Approved 17/04/2020, Institutional Review Board of Universidad San Francisco de Quito (Campus Cumbayá, Diego de Robles s/n, Quito 170901, Ecuador; comitebioetica@usfq.edu.ec; +593 2-297-1700), ref: CEISH 2020-025M",Ecuador,,"Results will be published in suitable clinical journals once results will be available. Also, results will be presented to local authorities and to general population through different media. IPD sharing statement: The datasets generated during and/or analyzed during the current study are/will be available upon request from Manuel E. Baldeon (manuel.baldeon@ute.edu.ec). All results will be available once the study will be concluded and data analyzed; data will be available for 6 months after publication. Data will be shared with scientists only with scientific purposes upon a written formal request. All participants have signed an informed consent. All data will be coded from the beginning of the study. Current study follows international and local ethics regulations.",Available on request,,,SalvarVidasEC,Universidad Tecnológica Equinoccial,grid.412257.7,,01/03/2021,11/03/2020,31/12/2020,10/05/2020,31/10/2020,08/05/2020,11/05/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,"This is a triple-blinded, two-arm, randomised controlled clinical trial",COVID-19 (SARS-CoV-2 infection) Respiratory COVID-19 (SARS-CoV-2 infection),Respiratory,,,University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Biological/Vaccine,Convalescent plasma obtained from previously infected and recovered COVID-19 patients,Phase II/III,Patient,Adult,Both,200,
1498,ISRCTN90906759,Investigating a vaccine against COVID-19,"CPMS 45551, IRAS 281904","Approved 08/04/2020, South Central - Berkshire Research Ethics Committee (Level 3, Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT, UK; +44 (0)2071048046; berkshire.rec@hra.nhs.uk), REC ref: 20/SC/0179",United Kingdom,,There are no plans currently to have any additional documents be available. Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date.,To be made available at a later date,,2020 results in https://pubmed.ncbi.nlm.nih.gov/33220855/ (added 19/11/2020) 2020 interim results in https://doi.org/10.1016/S0140-6736(20)32661-1 (added 09/12/2020) 2021 results in https://pubmed.ncbi.nlm.nih.gov/33617777/ (added 23/02/2021),National Institute for Health Research,University of Oxford,Missing GRID,http://dx.doi.org/10.13039/501100000272,31/03/2022,02/03/2020,30/09/2021,28/05/2020,30/09/2020,24/05/2021,07/05/2020,Ongoing,No longer recruiting,Prospectively registered,2020-001228-32,NCT04400838,"Single-blind randomized safety and efficacy study, with immunogenicity sub-studies in older and younger age groups",COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,government organisation,University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Biological/Vaccine,"ChAdOx1-nCoV19, MenACWY",Phase II/III,Healthy volunteer,Mixed,Both,12390,
1516,ISRCTN44152751,School opening in Norway during the COVID-19 pandemic,Nil known,"Current ethics approval as of 07/09/2020: 1. By 04/09/2020, the project had been rejected by Regional Ethics Committee South-East Norway, ref: 136575 2. Approval pending, National Ethical Board Previous ethics approval: Approval pending, The Regional Ethics Committee South-East Norway, ref: 136575",Norway,,"We intend to publish all trial results in public health journals. IPD sharing statement: The datasets generated during and/or analysed during the current study will be stored in a publically available repository (Norwegian Centre for Research Data, https://nsd.no/nsd/english/index.html). The dataset will include non-person identifiable data and be accessible at the time of publication or trial results, for anyone, and for all foreseeable future.",Stored in repository,,,Norwegian Institute of Public Health,Norwegian Institute of Public Health,grid.418193.6,,31/12/2020,18/03/2020,30/09/2020,11/05/2020,13/05/2020,07/09/2020,04/05/2020,Suspended,Suspended,Prospectively registered,Nil known,Nil known,Interventional cluster-randomized study,COVID-19 (SARS-CoV-2 infection) transmission in schools Infections and Infestations,Infections and Infestations,,,Research organisation,Cluster randomised trialCluster randomised trial,Community,Prevention,Other,,,Other,Child,Both,116750,
1552,ISRCTN13311119,START (Siddha Treatment Accelerating Recovery from SARS-CoV-2 Test) trial of Siddha treatment for patients with novel coronavirus infectious disease (COVID-19),NV-05-943-2020,"Approved 23/04/2020, Department of Health and Family Welfare of State of Tamil Nadu (Chennai 600009 India; +91 25671875, PABX-5671; hfsec@tn.gov.in)",India,,Results are intended to be presented as a Clinical Study Report or Publication. IPD sharing statement: The datasets generated during and/or analysed during the current study will be stored in a publically available repository,Stored in repository,,,Eminentlabs GmbH,Eminentlabs GmbH,Missing GRID,,26/06/2020,17/04/2020,26/06/2020,30/04/2020,20/05/2020,19/03/2021,24/04/2020,Completed,No longer recruiting,Prospectively registered,Nil known,Nil known,"A Multicenter, Randomized, Open-Label, Active-controlled Randomised Clinical Trial",COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,,Industry,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,"1. Kabasura kudineer, The Siddha Formulary of India 2. Brammanandha bairavam, Siddha vaithya thirattu",Phase II,Patient,Adult,Both,116,
1554,ISRCTN17898730,Expressive writing for the reduction of psychological difficulties during the COVID-19 pandemic,2020-20,"Approved 14/04/2020, Institutional Review Board (IRB) of the Department of Psychology, Faculty of Philosophy, University of Belgrade, Serbia (no tel. provided; komocetis@f.bg.ac.rs), ref: #2020-20",Serbia,,"The results will be published in the peer-reviewed journal. Furthermore, the results will be presented at scientific conferences and congresses. In addition, the findings’ summary for a lay audience will be created, circulated to local and international networks dealing with mental health interventions, and disseminated through social networks. IPD sharing statement: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Type of data: quantitative data - baseline and post-treatment assessment scores. Data will become available three months post-study completion and will be available indefinitely. Access criteria: the data will be shared with all interested researches or third parties who provide a reasonable explanation for the inquiry (replication, meta-analysis, etc.). Consent from participants was obtained to share data anonymously. Anonymization is ensured even at the data collection stage since all participants are taking part online using personalized passcode (the researchers are blind to participants personal information).",Available on request,,2020 results in https://pubmed.ncbi.nlm.nih.gov/33240180/ (added 27/11/2020),Psychosocial Innovation Network; Ministry for Education Science and Technological Development of the Republic of Serbia,Psychosocial Innovation Network,Missing GRID,,31/12/2021,21/03/2020,20/12/2020,07/04/2020,14/04/2020,27/11/2020,23/04/2020,Completed,No longer recruiting,Retrospectively registered,Nil known,Nil known,Between-subjects pre-test post-test randomized controlled trial,"Depression, anxiety, and stress-related difficulties Mental and Behavioural Disorders",Mental and Behavioural Disorders,,,Other,Randomised controlled trialRandomised controlled trial,Internet,Quality of life,Behavioural,,,Healthy volunteer,Adult,Both,150,120.0
1596,ISRCTN14326006,Does taking hydroxychloroquine before and during exposure to patients protect frontline healthcare workers from coronavirus?,HEROs Protocol 1.1,"Approved 08/04/2020, Clinical Trials Ontario - University Health Network Research Ethics Board (10th Floor, Room 1056, 700 University Avenue, Toronto, ON, M5G 1Z5, Canada; +1 (0)416 581 7849; boardofrecord@uhnresearch.ca), ref: CTO Project ID: 2132",Canada,,"Following the completion of the study, the lead Principal Investigator is expected to publish the results of the primary and secondary analyses from this trial in peer-reviewed scientific journals. IPD sharing statement At the time of completion of the analysis of primary and secondary outcomes, the HEROS Steering Committee will review all applications for use of participant-level data and make recommendations. The contact will be Megan Landes (megan.landes@uhn.ca).",Other,,2020 structured summary of protocol in https://pubmed.ncbi.nlm.nih.gov/32665039/ (added 17/07/2020),Canadian Institutes of Health Research; National Research Council Canada,University Health Network,grid.231844.8,http://dx.doi.org/10.13039/501100000024; http://dx.doi.org/10.13039/501100000046,30/01/2022,29/03/2020,30/01/2022,13/04/2020,30/07/2021,20/07/2020,14/04/2020,Ongoing,Recruiting,Retrospectively registered,Nil known,Nil known,Multicentre double-blinded randomized placebo-controlled trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,government organisationgovernment organisation,Hospital/treatment centre,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Drug,Hydroxychlorquine,Phase III,Health professional,Adult,Both,988,
1614,ISRCTN43900695,Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic,V1.0 (20 July 2020),"Approved 09/04/2020, Northumbria University (Department of Psychology, Northumbria University, Newcastle-upon-Tyne, UK; no tel. provided; nick.neave@northumbria.co.uk), ref: 23377",United Kingdom,,"Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Dr Greg Elder (g.elder@northumbria.ac.uk) after a period of exclusive use (12 months). Our intended policy is that the research team will have exclusive use of the data for a period of 12 months from the end of the project, or until the data is published, if this is required alongside publications. Anonymised data will be provided and data will be made available upon application and the research team would control access in line with Northumbria University guidelines, however, data access will not reasonably be refused.",Available on request,,2020 protocol in https://pubmed.ncbi.nlm.nih.gov/32771068/ (added 13/08/2020),Northumbria University,Northumbria University,grid.42629.3b,http://dx.doi.org/10.13039/100010052,01/04/2022,25/03/2020,06/04/2022,17/08/2020,01/04/2022,06/10/2020,08/04/2020,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,Interventional cluster randomized trial,Acute insomnia Mental and Behavioural Disorders,Mental and Behavioural Disorders,,,University/education,Cluster randomised trialCluster randomised trial,Internet,Treatment,Behavioural,,,Mixed,Adult,Both,60,
1626,ISRCTN15281137,"A phase I/II study to determine efficacy, safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers","CPMS 45367, IRAS 281259","Approved 26/03/2020, South Central Berkshire REC (Level 3, Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT, UK; +44 (0)2071048046; berkshire.rec@hra.nhs.uk), ref: 20/SC/0145",United Kingdom,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date.,To be made available at a later date,,2020 preliminary results in https://pubmed.ncbi.nlm.nih.gov/32702298/ (added 20/07/2020) 2020 interim results in https://doi.org/10.1016/S0140-6736(20)32661-1 (added 09/12/2020) 2021 results in https://pubmed.ncbi.nlm.nih.gov/33617777/ (added 23/02/2021) 2021 results of efficacy against in SARS-CoV-2 variant B.1.1.7 in https://pubmed.ncbi.nlm.nih.gov/33798499/ (added 06/04/2021),UK Research and Innovation,University of Oxford,grid.4991.5,http://dx.doi.org/10.13039/100014013,31/12/2021,02/03/2020,30/11/2021,26/03/2020,24/04/2020,24/05/2021,06/04/2020,Ongoing,No longer recruiting,Retrospectively registered,2020-001072-15,NCT04324606,Interventional randomized controlled trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations,Infections and Infestations,,private sector organisation,University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Prevention,Biological/Vaccine,ChAdOx1 nCoV-19 (AZD1222),Phase I/II,Patient,Adult,Both,1112,1077.0
1628,ISRCTN16912075,"RECOVERY Respiratory Support: Respiratory Strategies in patients with coronavirus COVID-19 – CPAP, high-flow nasal oxygen, and standard care","Sponsor: 26/19-20, IRAS 282338","Approved 03/04/2020, the London - Brighton & Sussex Research Ethics Committee (Health Research Authority, Ground Floor, Skipton House, 80 London Road, London SE1 6LH; +44 0207 104 8241; brightonandsussex.rec@hra.nhs.uk), ref: 20/HRA/1696",United Kingdom,,Trial results will be published as soon as data are analysed. Dissemination will include development of lay summaries and publication in a peer-reviewed journal. IPD sharing statement: The data sharing plans for the current study are unknown and will be made available at a later date,To be made available at a later date,,2020 protocol in https://pubmed.ncbi.nlm.nih.gov/32727624/ (added 03/08/2020),National Institute for Health Research,University of Warwick,grid.7372.1,http://dx.doi.org/10.13039/501100000272,03/10/2021,30/03/2020,02/06/2021,06/04/2020,03/05/2021,05/05/2021,06/04/2020,Completed,No longer recruiting,Prospectively registered,Nil known,Nil known,"Adaptive (group-sequential), pragmatic, randomised controlled, open-label, multi-centre, effectiveness trial",Respiratory failure in patients with known or suspected COVID-19 (SARS-CoV-2 infection) Respiratory COVID-19 (SARS-CoV-2 infection),Respiratory,,government organisation,University/education,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Procedure/Surgery,,,Patient,Adult,Both,4002,
1660,ISRCTN83971151,Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients,0003361,"Approved 04/05/2020, WHO Research Ethics Review Committee (20, Avenue Appia – Ch-1211 Geneva 27 – Switzerland; +41 227573052; ercsec@who.int), ref: ERC.0003361",Argentina; Brazil; Canada; Germany; Honduras; India; Indonesia; Iran; Ireland; Israel; Italy; Kenya; Lebanon; Malaysia; Norway; Peru; Philippines; Qatar; Saudi Arabia; South Africa; Spain; Switzerland; Thailand,,"This international collaboration is co-ordinated through the World Health Organization, which is also a sponsor of the trial. Any wholly reliable interim findings will be disseminated rapidly by the WHO. There will be group authorship recognizing the contribution of all national and local investigators and guided by the International Committee of Medical Journal Editors (ICMJE) recommendations. IPD sharing statement: The current data sharing plans for this study are unknown and will be available at a later date.",To be made available at a later date,,"2020 interim non-peer-reviewed results in preprint https://doi.org/10.1101/2020.10.15.20209817 (added 19/10/2020) 2021 interim results for remdesivir, hydroxychloroquine, lopinavir and interferon in https://pubmed.ncbi.nlm.nih.gov/33264556/ (added 25/03/2021)",World Health Organization,World Health Organization,grid.3575.4,http://dx.doi.org/10.13039/100004423,31/12/2021,01/03/2020,25/03/2021,26/03/2020,28/02/2021,25/03/2021,25/03/2020,Completed,No longer recruiting,Prospectively registered,Nil known,Nil known,Open-label randomized multicountry clinical trial,COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection),Infections and Infestations,,private sector organisation,Government,Randomised controlled trialRandomised controlled trial,Hospitals,Treatment,Drug,"Remdesivir, chloroquine or hydroxychloroquine, lopinavir + ritonavir (Kaletra), interferon-beta",Phase III,Patient,Adult,Both,10000,11266.0
1666,ISRCTN86534580,PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home,IRAS 281958,"Approved 26/03/2020, NHS REC South Central - Berkshire (Health Research Authority, Skipton House, 80 London Road, London, SE1 6LH, UK; +44 (0)2071048046; berkshire.rec@hra.nhs.uk), ref: 20/SC/0158",United Kingdom,,"Planned publication in a high-impact peer-reviewed journal. IPD sharing statement Selected, de-identified individual participant data for outcome measures will be available on request, accompanied by a protocol outlining hypotheses and proposed analytic methods, by contacting the corresponding author: requests will be considered by a Departmental Committee. A contract should be signed.",Available on request,,2021 azithromycin results in https://pubmed.ncbi.nlm.nih.gov/33676597/ (added 08/03/2021) 2021 non-peer-reviewed budesonide results in preprint https://doi.org/10.1101/2021.04.10.21254672 (added 13/04/2021) 2021 protocol in https://pubmed.ncbi.nlm.nih.gov/34145016/ (added 21/06/2021),Office of the Chief Medical Officer,University of Oxford,grid.4991.5,,24/03/2022,12/03/2020,24/09/2022,25/03/2020,30/04/2022,21/06/2021,22/03/2020,Ongoing,Recruiting,Prospectively registered,2020-001209-22,Nil known,Pragmatic platform randomized controlled trial of interventions for COVID-19 in primary care,"COVID-19 (SARS-CoV-2 infection) Infections and Infestations Coronavirus infection, unspecified site",Infections and Infestations,,,University/education,Randomised controlled trialRandomised controlled trial,Community,Treatment,Drug,"azithromycin, hydroxychloroquine sulphate, doxycycline, inhaled budesonide (Pulmicort turbohaler®), colchicine, favipiravir, ivermectin",Phase III,Patient,Adult,Both,6000,
1673,ISRCTN14966673,Does point-of-care testing for coronavirus in hospital improve patient care compared to laboratory testing?,"RHM MED1696, IRAS 280621","Approved 16/03/2020, Substantial Amendment 1 approved 23/06/2020, South Central - Hampshire A Research Ethics Committee (Level 3, Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT, UK; +44 (0)207 104 8033, hampshirea.rec@hra.nhs.uk), ref: 20/SC/0138",United Kingdom,,"No additional study documentation is available at this time although the protocol will be subsequently published. The results will be published in high-impact scientific journals and presented at national and international conferences - dependent on travel restrictions. IPD sharing statement The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Tristan Clark (t.w.clark@soton.ac.uk). Data will be made available in 3 months following publication for a period of 5 years. All of the individual participant data collected during the trial, after de-identification will be made available. It will be available to researchers who provide methodologically sounds proposal to achieve the aims in the approved proposal including individual participant meta-analysis. Proposals should be directed to the above PI. All data will be de-identified. Informed consent will be obtained from all patients. There are no known ethical or legal restrictions currently.",Available on request,,2020 results in https://pubmed.ncbi.nlm.nih.gov/33038974/ (added 13/10/2020),University Hospital Southampton NHS Foundation Trust,University Hospital Southampton NHS Foundation Trust,grid.430506.4,http://dx.doi.org/10.13039/100010417,01/04/2021,07/02/2020,01/04/2021,20/03/2020,29/04/2020,13/10/2020,18/03/2020,Completed,No longer recruiting,Prospectively registered,Nil known,Nil known,Prospective interventional non-randomised controlled study,"COVID-19 (SARS-CoV-2 infection) Infections and Infestations Coronavirus infection, unspecified site",Infections and Infestations,,government organisation,Hospital/treatment centre,Non randomised studyNon randomised study,Hospitals,Diagnostic,Other,,,Patient,Adult,Both,1000,1055.0
1741,ISRCTN14966097,"Exploring the impact on patients with lupus and related autoimmune diseases of peer support, relationships with clinicians and COVID-19 changes to care",PRE.2019.099,"Approved 30/01/2020, Cambridge Psychology Research Ethics Committee (School of the Biological Sciences, 17 Mill Lane, Cambridge, UK; no tel. provided; cheryltorbett@admin.cam.ac.uk), ref: PRE.2019.099",United Kingdom,,"This research should generate three publications in rheumatology journals. The first phase will lead to a paper on the impact/acceptability/feasibility of small group peer support. The second phase will report physician views and the large scale questionnaire results will be reported in a paper on the diagnostic journey, patient trust in physicians and mental health/wellbeing. IPD sharing statement The datasets generated during and/or analysed during the current study are not expected to be made available due to lack of consent.",Not expected to be available,,,LUPUS UK,University of Cambridge,grid.5335.0,,01/06/2021,01/03/2020,01/04/2021,02/03/2020,06/03/2020,30/03/2021,27/02/2020,Completed,No longer recruiting,Prospectively registered,Nil known,Nil known,Interventional randomized controlled trial,Lupus and other related SARDs/CTDs (systemic autoimmune rheumatic diseases/connective tissue diseases) Skin and Connective Tissue Diseases Lupus erythematosus,Skin and Connective Tissue Diseases,,,University/education,Randomised controlled trialRandomised controlled trial,Internet,Quality of life,Behavioural,,,Patient,Adult,Both,180,139.0
1779,ISRCTN47591507,Treating auditory impairment and cognition pilot trial,"18/0079, IRAS 246188","Current ethics approval as of 01/03/2021: 1. Approved 24/08/2018, London - Surrey Research Ethics Committee (Health Research Authority, Skipton House, 80 London Road, London, SE1 6LH, UK; +44 (0)207 104 8222; NRESCommittee.SECoast-Surrey@nhs.net), ref: 18/LO/1196 2. TACT Remote Hearing Intervention Sub-study substantial amendment approved 25/09/2020, London - Surrey Research Ethics Committee (Health Research Authority, Skipton House, 80 London Road, London, SE1 6LH, UK; +44 (0)207 104 8222; NRESCommittee.SECoast-Surrey@nhs.net), ref: 18/LO/1196 Previous ethics approval: Approved 24/08/2018, London - Surrey Research Ethics Committee (Health Research Authority, Skipton House, 80 London Road, London, SE1 6LH, UK; +44 (0)207 104 8222; NRESCommittee.SECoast-Surrey@nhs.net), ref: 18/LO/1196",United Kingdom,,Planned publication in a high-impact peer-reviewed journal. IPD sharing statement: All data generated or analysed during this study will be included in the subsequent results publication.,Other,,,Alzheimer’s Research UK,University College London,grid.83440.3b,http://dx.doi.org/10.13039/501100002283,30/06/2022,01/02/2018,28/02/2021,22/10/2018,15/01/2021,01/03/2021,20/02/2020,Suspended,Suspended,Retrospectively registered,Nil known,Nil known,Single-centre randomized unblinded parallel pilot trial with a single-arm non-randomised remote intervention sub-study,"Mild cognitive impairment and hearing loss Nervous System Diseases Mild cognitive disorder, hearing loss",Nervous System Diseases,,private sector organisation,University/education,Randomised parallel trialRandomised parallel trial,Home,Prevention,Behavioural,,,Patient,Mixed,Both,76,
1892,ISRCTN37530113,Enhanced cognitive behavioral therapy for children and adolescents with obsessive compulsive disorder: an open trial,Samarbeidsorganet mellom Helse Midt-Norge RHF project nr 90023600,"Current ethics approval as of 11/06/2020: Approved 18/05/2016, amendment approved 26/05/2020, Regional Committees for Medical and Health Research Ethics (REK nord; UiT Norges arktiske universities, Postboks 6050 Langnes, 9037 Tromsø, Norway; Tel: +47 (0)77 64 61 40; Email: rek-nord@asp.uit.no), ref: 2016/716/REK nord Previous ethics approval: Approved 18/05/2016, Regional Committees for Medical and Health Research Ethics (REK nord; UiT Norges arktiske universitet Postboks 6050 Langnes, 9037 Tromsø, Norway; Tel: +47 (0)77 64 61 40; Email: rek-nord@asp.uit.no), ref: 2016/716/REK nord",Norway,,"The researchers expect that the study protocol will become available in the summer of 2020 (updated 11/06/2020; previously: upcoming months [March 2020]). Peer-reviewed publications: scientific papers and presentations reflecting different stages of the project are planned. Outcomes will also be presented at regional, national and international conferences. Educational workshops are planned for service providers and service users. Media activities: local and national TV, radio and print media will be approached to disseminate findings from the project. IPD sharing statement The datasets generated during and/or analysed during the current study will be stored in a non-publically available repository at the Department of Mental Health, RKBU, Norwegian University of Science and Technology, Klostergata 46, 7030, Trondheim, Norway. Data includes demographics and baseline characteristics of the participants, and assessment of symptoms during and following treatment. The information will be entered by the Data Manager. All relevant data will be entered into a separate anonymous password protected and encrypted file, protection of participants’ identity will be guaranteed by assigning study-specific unique subject codes. Codes will be used to conceal identities in all external communication. Rechecks or later use of the data will be possible using the anonymized data file. Later use of the data will only be possible with the consent of the participant. Information (raw data) will be kept for 10 years. Informed consent is obtained from all participants before study participation. The study will be conducted according to the principles of the Declaration of Helsinki (version 19th October 2013; WMA, 2013).",Stored in repository,,2020 protocol in https://pubmed.ncbi.nlm.nih.gov/33203621/ (added 19/11/2020),Norges Teknisk-Naturvitenskapelige Universitet,Central Norway Regional Health Authority,grid.453770.2,http://dx.doi.org/10.13039/100009123,31/12/2021,01/10/2015,31/12/2021,04/09/2017,31/12/2021,09/12/2020,31/01/2020,Ongoing,Recruiting,Retrospectively registered,Nil known,Nil known,Single-center open trial with quasi-experimental design (historical control),Pediatric OCD Mental and Behavioural Disorders Obsessive-compulsive disorder,Mental and Behavioural Disorders,,private sector organisation,Government,Non randomised studyNon randomised study,Other,Treatment,Behavioural,,,Patient,Child,Both,70,
1995,ISRCTN10974028,Language intervention in the early years - comparing the effectiveness of language intervention approaches for pre-school children with language difficulties,LIVELY-2019,"Approved 11/10/2019, University of Newcastle Ethics Committee (Faculty of Humanities and Social Sciences, Great North House, Sandyford Road, Newcastle upon Tyne, NE1 8ND, UK; Tel: +44 (0)191 208 6349; Email: Wendy.Davison@ncl.ac.uk), ref: 15153",United Kingdom,,"Planned publication in a high-impact peer-reviewed journal. The researchers are not currently planning to publish any additional documents. They may decide to publish the data analysis plan prior to data analysis. IPD sharing statement At the end of the project, once resulting publications have been accepted, the data collected will be de-identified and made available as “open data” through a research data repository (https://research.ncl.ac.uk/rdm/sharing/). This means the de-identified study data will be publicly available and may be used by other researchers for purposes not related to this study. It will not be possible to identify the children or schools from the “open data”. Parents/carers, headteachers, teachers and teaching assistants will be asked to sign consent forms prior to data collection starting.",Stored in repository,,,Heather van der Lely Foundation,Newcastle University,grid.1006.7,,01/10/2022,11/07/2019,01/10/2021,01/02/2020,01/10/2021,08/03/2021,08/01/2020,Ongoing,Recruiting,Prospectively registered,Nil known,Nil known,Cluster randomised control trial,"Language disorder Mental and Behavioural Disorders Developmental disorder of speech and language, unspecified",Mental and Behavioural Disorders,,,University/education,Cluster randomised trialCluster randomised trial,Schools,Treatment,Behavioural,,,Other,Child,Both,104,
